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ABSTRACT	
Background:	 	 Chronic	 Obstructive	 Pulmonary	 Disease	 (COPD)	 is	 a	 complex,	 progressive	
respiratory	condition.	There	is	growing	evidence	that	people	with	COPD	may	experience	some	
degree	 of	 cognitive	 dysfunction.	 Most	 COPD	 patients	 maintain	 relatively	 long	 periods	 of	
stable	health.	Despite	this,	previous	reviews	on	this	topic	have	included	both	exacerbating	
and	stable	samples	and	investigations	have	been	limited	to	examine	only	general	cognitive	
function.	 Such	 approaches	 reduce	 the	 generalisability	 and	 clinical	 utility	 of	 findings	 and	
confound	any	conclusions	drawn.	Therefore,	at	present,	the	nature	of	cognitive	dysfunction	
in	stable	COPD	remains	poorly	understood.		
Objective:	To	examine	the	literature	comparing	domain-specific	cognitive	function	in	stable	
COPD	patients	and	controls.		
Methods:	After	screening	679	potentially	relevant	articles,	11	met	inclusion	criteria	for	this	
narrative	 review.	 All	 studies	 were	 quality	 rated	 using	 a	 protocol	 developed	 from	 SIGN	
Methodology	Checklist	4.		
Results:		Stable	COPD	patients	consistently	attained	significantly	lower	scores	than	controls	
across	 several	 cognitive	domains,	 including	processing	speed,	memory,	concept	 formation	
and	abstract	reasoning,	and	executive	functions.		
Conclusions:	COPD	patients	may	be	at	 risk	of	experiencing	cognitive	difficulties,	even	 in	a	
stable	 phase	 of	 the	 disease.	While	 a	 definitive	 cognitive	 profile	 of	 stable	 COPD	 was	 not	
identified,	cognitive	dysfunction	observed	in	this	population	may	have	implications	for	clinical	
care.			
	
Key	words:	Chronic	Obstructive	Pulmonary	Disease;	Cognitive	Function;	Neuropsychological	
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INTRODUCTION	
Chronic	Obstructive	Pulmonary	Disease	(COPD)	is	a	progressive	respiratory	condition	marked	
by	irreversible	airway	inflammation.	COPD	Is	the	UK’s	fifth	leading	cause	of	mortality	(Snell	et	
al.,	 2016)	 and	 is	 largely	 associated	with	 chronic	 exposure	 to	 environmental	 pollutants	 or	
smoking	 (Global	 Initiative	 for	 Chronic	 Obstructive	 Lung	 Disease	 (GOLD),	 2016).	 Primary	
symptoms	 include	breathlessness,	 chronic	 cough	 and	 sputum	production.	However,	more	
recently,	COPD	management	guidelines	are	moving	towards	a	multifactorial	disease	model	
which	extends	beyond	the	lungs.	This	approach	aims	to	address	the	interaction	of	primary	
disease-specific	factors	with	secondary	related	issues,	such	a	comorbidities	and	lifestyle,	and	
wider	demographic	characteristics.		
	
Comorbidities	 are	 common	 in	 COPD	 patients.	 Secondary	 cardiovascular	 problems	 are	
frequently	observed	(Barnes	and	Celli,	2009)	alongside	conditions	such	as	diabetes	(Feary	et	
al.,	 2010);	 cancer	 (Anthonisen	 et	 al.,	 2002);	 sleep	 apnoea	 (McNicholas,	 2016)	 and	mood	
disorders	 (Hynninen	 et	 al.,	 2005).	 Given	 such	 circumstances,	 clinicians	 are	 increasingly	
recognising	the	necessity	of	whole-patient	approaches,	incorporating	routine	screening	and	
clinical	management	considerations	for	all	relevant	comorbidities	(Dodd,	Getov	and	Jones,	
2010).	 In	 line	with	 these	developments,	 recent	attention	has	been	given	 to	 the	anecdotal	
accounts	 of	 memory	 problems	 and	 “brain	 fog”	 which	 are	 commonly	 reported	 by	 COPD	
patients.	Indeed,	given	that	primary	disease	presentation	directly	influences	circulating	blood	
gases,	it	may	be	reasonable	to	expect	that	some	damage	or	dysfunction	to	oxygen-sensitive	
brain	 regions	 could	 arise	 in	 this	 condition	 (Paola	 et	 al.,	 2008).	 Several	 recent	
neuropsychological	 literature	 reviews	 have	 explored	 the	 relationship	 between	 COPD	 and	
brain	 function	 (Hynninen	 et	 al.,	 2005;	 Dodd,	 Getov	 and	 Jones,	 2010;	 Schou	 et	 al.,	 2012;	
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Cleutjens	et	al.,	2014;	Lahousse	et	al.,	2015;	Torres-Sánchez	et	al.,	2015).	However,	 these	
studies	have	varied	in	methodological	approaches	and	findings	have	been	mixed.		Therefore,	
at	present,	 the	pattern	and	nature	of	cognitive	difficulties	arising	 in	this	condition	are	still	
poorly	understood	and	further	investigation	is	required.		
	
The	pathology	underlying	 cognitive	dysfunction	 in	COPD	 is	 complex	and,	 to	date,	 remains	
unclear.	Several	authors	have	endeavoured	 to	 identify	 the	potential	mechanisms	 involved	
(Borson	 et	 al.,	 2008;	 Dodd,	 Getov	 and	 Jones,	 2010;	 Cleutjens	 et	 al.,	 2014).	 While	 some	
associations	between	cognitive	abilities	and	disease	severity	have	been	found	(Schou	et	al.,	
2012),	 there	 is	mounting	 literature	 addressing	 the	 role	 of	 circulating	 blood-gases.	 Several	
papers	have	demonstrated	a	 relationship	between	hypoxemia	 (abnormally	 low	circulating	
oxygen	levels),	and	to	a	lesser	extent	hypercapnia	(abnormally	high	circulating	carbon	dioxide	
levels),	 and	 neuropsychological	 performance	 (Dodd,	 Getov	 and	 Jones,	 2010).	 Blood-gases	
have	also	been	linked	to	changes	in	cerebral	perfusion	and	neurotransmitter	levels	(Shim	et	
al.,	2001).	
	
The	 consideration	of	 disease-specific	 variables	 is	 complicated	 further	 by	 the	dynamic	 and	
phasic	nature	of	COPD.		At	any	one	time,	the	majority	of	patients	are	considered	“stable”,	
their	illness	remains	well	controlled	and	changes	in	health,	treatment	needs	or	functioning	
are	relatively	minor.	Indeed,	a	central	aim	of	COPD	management	is	the	maintenance	of	such	
stability	 and	 prevention	 of	 exacerbations:	 “acute	 events	 characterised	 by	 a	 worsening	 of	
symptoms	 beyond	 normal	 day-to-day	 variations”(GOLD,	 2016).	 Exacerbations	 commonly	
present	 as	 diminished	 health	 status	 marked	 by	 increased	 breathlessness	 and	 respiratory	
infection.	These	acute	episodes	usually	necessitate	periods	of	close	monitoring	and	additional	
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treatment,	often	requiring	hospitalisation.	While	the	link	between	exacerbation	and	cognitive	
function	 is	unclear,	 it	has	been	suggested	that	physiological	dysregulation,	as	experienced	
during	 exacerbation,	 may	 increase	 risk	 of	 cognitive	 difficulties,	 whether	 transient	 or	
permanent	(Dasgupta,	2016).	 	Furthermore,	the	multifaceted	influence	of	COPD	pathology	
may	dynamically	interact	with	comorbidities,	many	of	which	may	exert	independent	influence	
on	brain	function,	marking	a	complex	pathway	to	cognitive	impairment.		
	
Despite	the	complexity	of	contributing	factors,	it	is	important	to	understand	the	nature	of	any	
cognitive	 difficulties	 arising	 in	 COPD.	 Evidence	 from	 other	 chronic	 health	 conditions	 has	
demonstrated	relationships	between	cognitive	dysfunction	and	a	range	of	clinical	outcomes.		
Difficulties	with	disease	management	and	medication	adherence	has	been	associated	with	
cognitive	problems	 in	heart	 failure	and	diabetes	 (Alosco	et	al.,	2012;	Hopkins,	Shaver	and	
Weinstock,	 2016).	 Additionally	 cognitive	 difficulties	 have	 been	 linked	 to	 reductions	 in	
activities	of	daily	living	in	chronic	kidney	disease	(Goto,	2017)	and	quality	of	life	in	multiple	
sclerosis	 (Benito-Leon,	 Morales	 and	 Rivera-Navarro,	 2002).	 In	 the	 current	 healthcare	
landscape	of	increasing	emphasis	on	self-management,	it	is	important	that	considerations	of	
cognitive	difficulties	are	incorporated	into	treatment	guidelines.		Neglecting	to	acknowledge	
such	 issues	may	 lead	 to	 poor	 disease	management	 causing	more	 frequent	 exacerbations,	
related	hospital	admissions	and	reliance	on	care.	
	
Comprehensive	neuropsychological	assessment	should	cover	a	range	of	cognitive	domains,	
each	having	a	differential	impact	on	functional	abilities.	A	commonly	accepted	classification	
system	will	be	used	in	this	study	(Lezak	et	al.,	2012).	Processing	speed	is	defined	as	simple	
mental	speed,	often	measured	by	reaction	times,	while	working	memory	and	attention	tasks	
	 11	
examine	 an	 individual’s	 limited	 attentional	 capacity.	 Perception	 is	 the	 ability	 to	 take	 in	
information	from	the	environment.	Memory	is	the	capacity	to	retain	information	and	later	
utilise	it	for	adaptive	purposes.	Tasks	examining	language	and	verbal	abilities	typically	involve	
object	naming.	Motor	abilities	are	closely	linked	to	processing	speed	but	may	also	examine	
abilities	 of	 fine-motor	 dexterity	 and	 manipulation,	 while	 constructional	 abilities	 combine	
visuospatial	perception	with	motor	response.	Concept	formation	involves	abstract	reasoning	
and	thinking	abilities.	Executive	functions	are	examined	on	tasks	assessing	planning,	problem	
solving,	self-monitoring	and	behavioural	regulation.		
	
Previous	systematic	reviews	examining	cognitive	dysfunction	in	COPD	have	varied	in	scope	
and	methodology	 (Hynninen	et	al.,	 2005;	Schou	et	al.,	 2012;	Torres-Sánchez	et	al.,	 2015).	
Many	 have	 taken	 an	 inclusive	 approach	 to	 study	 selection	 with	 regards	 to	 sample	
characteristics.	Included	samples	have	originated	from	a	wide	variety	of	sources	with	many	
recruiting	via	inpatient	respiratory	services.	As	such,	a	large	proportion	of	participants	were	
exacerbating	 COPD	 patients.	 While	 insights	 into	 cognitive	 function	 during	 exacerbation	
contribute	to	the	overall	picture	of	this	condition,	exacerbation	phases	tend	to	cover	brief	
periods	in	the	lifecycle	of	the	disease.	Furthermore,	self-management	abilities	are	likely	to	
have	more	 impact	 upon	 outcomes	 in	 a	 stable	 phase,	 thus	 knowledge	 regarding	 cognitive	
function	 during	 exacerbation	 is	 limited	 in	 its	 clinical	 utility.	 	 Finally,	 undifferentiated	
assessment	 of	 stable	 and	 exacerbating	 patients	 introduces	 a	 meaningful	 confound,	 thus	
reducing	 the	 strength	 of	 conclusions	 drawn.	 Therefore,	 this	 review	 aims	 to	 examine	 the	
literature	investigating	cognitive	function	in	stable	COPD	and	address	the	following	questions:	
(1)	What	 is	 the	nature	of	cognitive	dysfunction	 in	stable	COPD?	 (2)	 Is	 there	a	 relationship	
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between	 cognitive	 dysfunction	 and	 disease-specific	 variables	 such	 as	 lung	 function	 and	
arterial	blood-gases	(ABGs)?		
METHODS	
	
All	studies	examining	cognitive	performance	in	stable	COPD	were	eligible	for	inclusion	in	this	
systematic	 review.	 	 A	 search	 of	 the	 term	 “Chronic	 Obstructive	 Pulmonary	 Disease”	 on	
PROSPERO	found	no	ongoing	systematic	reviews	on	this	topic.		
	
Database	searches		
The	 search	 strategy	was	 customised	 for	 each	 database	 and	 utilised	 controlled	 vocabulary	
(MeSH)	and	keywords.	The	following	databases	were	systematically	searched:	Medline	(via	
Ovid	Medline	(R)	1946	to	week	1	January	2018	and	OVID	Medline	(R)	in-process	and	other	
non-indexed	 citations),	 EMBASE	 (via	Ovid,	 1947	 to	 present,	 updated	 daily	 on	 21st	 January	
2018),	CINAHL,	PsycInfo,	Psychology	and	Behavioural	Science	Collection	(via	EBSCOhost	1987	
until	21st	January	2018),	Web	of	Science	(inception	date	of	database	until	21st	January	2018).	
	
Using	Boolean	operators	‘AND’	and	‘OR’	in-between	as	specified,	the	following	search	terms	
were	used:		
1. Chronic	 Obstructive	 Pulmonary	 Diseas*	 OR	 copd	 OR	 Pulmonary	 Disease,	 Chronic	
Obstructive	(MeSH)		
2. Cognitive	OR	Cognition	OR	Cognition	disorders	(MeSH)	OR	Cognitive	defect	 (MesH)	
OR	 Cognition	 (Mesh)	 OR	 neuropsychol*	 OR	 Neuropsychological	 Tests	 (MesH)	 OR	
Neuropsychology	(MeSH)	
3. Stable		
4. 1	AND	2	AND	3	
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Hand-searching	of	 included	studies	reference	 lists	was	subsequently	conducted	to	 identify	
any	articles	not	found	by	electronic	searches.		
Studies	meeting	the	following	criteria	were	included:	(i)	published	in	English,	(ii)	human	adult	
participants,	(iii)	original	published	research,	(iv)	case-control	design,	(v)	participants	have	a	
diagnosis	 of	 COPD	 which	 is	 classified	 as	 stable,	 (vi)	 study	 provides	 a	 neuropsychological	
measure	 of	 function	 in	 a	 specific	 cognitive	 domain(s).	 Studies	 that	 reported	 only	 general	
cognitive	ability,	 for	example	 total	Montreal	Cognitive	Assessment	 scores,	were	excluded.			
The	 article	 selection	 process	 is	 illustrated	 in	 Figure	 1.	 If	 suitability	 for	 inclusion	 was	
ambiguous,	an	independent	researcher	examined	the	article.		
	
Quality	Rating		
Study	 quality	 was	 examined	 using	 an	 adapted	 version	 of	 the	 Scottish	 Intercollegiate	
Guidelines	Network	(SIGN)	Methodology	Checklist-4:	Case-control	studies	(2008)	[Appendix	
1.2].	This	protocol	consists	of	nine	items	covering	five	methodological	issues:	study	question,	
subject	 selection,	 assessment,	 confounding	 factors	 and	 statistical	 analysis.	 Each	 item	was	
answered	 ‘yes’,	 ‘no’	 or	 ‘can’t	 say’.	 The	 overall	 methodological	 quality,	 dependent	 upon	
number	of	‘yes’	responses,	was	rated	as	‘high	quality’	(++)	(six	or	more),	‘acceptable’	(+)	(four	
or	five),	or	‘low	quality’	(0)	(less	than	four).	A	second	rater	also	assessed	five	of	the	included	
papers	to	ensure	reliability.	The	selected	papers	were	separately	rated	by	each	reviewer	and	
disagreements	 were	 resolved	 through	 discussion	 with	 final	 ratings	 amended	 to	 the	
consensus.	Initial	agreement	in	overall	quality	was	found	for	four	co-rated	papers.		
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Data	Synthesis	and	Extraction		
A	meta-analysis	was	not	considered	appropriate	due	to	variation	in	methodology,	measures	
of	cognitive	function	and	statistical	analysis.	Therefore,	a	narrative	synthesis	was	undertaken	
(Popay	et	al.,	2006).	A	data	extraction	form	was	used	to	systematically	collect	information	on	
sample	characteristics,	recruitment,	neuropsychological	measures	and	results	for	every	study	
[Appendix	1.3].	Statistically	significant	differences	in	cognitive	performance	between	COPD	
and	 control	 groups	were	explored.	However,	 the	 studies	 included	 in	 this	 review	varied	 in	
sample	 sizes	 and	 statistical	 power.	 Therefore,	 data	 reporting	 which	 is	 limited	 to	 only	
statistically	significant	between-group	differences	may	lead	to	inaccurate	interpretations	of	
findings.	Such	results	do	not	speak	to	the	magnitude	of	the	between-group	differences	and,	
as	such,	have	limited	clinical	meaning.	To	address	this	issue,	Cohen’s	d	effect	sizes	were	also	
calculated,	where	possible,	for	individual	cognitive	measures	within	each	study.	
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RESULTS	
	
Search	results		
As	 illustrated	 in	Figure	1,	 the	 literature	 search	 initially	 identified	679	papers	 for	 inclusion.	
After	the	exclusion	of	duplicates	and	unrelated	studies,	96	papers	were	reviewed	at	abstract	
level	and	35	full	texts	were	subsequently	reviewed.	Eleven	papers	met	final	inclusion	criteria.		
	
Study	characteristics		
Table	1	summarises	the	characteristics,	quality	ratings	and	main	findings	of	included	studies.		
In	 addition	 to	 stable	 COPD	 participants	 and	 healthy	 controls,	 some	 studies	 also	 included	
participants	during	exacerbation	(Dodd	et	al.,	2013),	Alzheimer’s	patients	and	older-healthy	
volunteers	(Incalzi	et	al.,	1997).	However,	the	current	review	has	focussed	on	results	of	stable	
COPD	participants	and	matched	controls.	A	wide	range	of	neuropsychological	measures	were	
employed	and	each	domain	was	explored	by	at	least	two	papers.		
	
Overall,	ten	studies	reported	on	disease	severity	and	seven	examined	the	relationship	with	
cognitive	performance.		Historically,	COPD	severity	has	been	quantified	by	degree	of	airflow	
limitation,	measured	by	forced	expiratory	volume	in	one	second	(FEV1)	as	a	percentage	of	
demographic-predicted	 FEV1(FEV1%pred.).	 Prior	 to	 2011,	GOLD	promoted	 the	 adoption	of	
severity	 classification	 ranges	 (mild	 to	very	 severe)	based	on	 solely	FEV1(%pred.)	 values.	 In	
accordance	with	these	guidelines,	two	studies	reported	the	number	of	participants	in	each	
severity	range	(Borson	et	al.,	2008;	Zhang	et	al.,	2012),	while	a	 further	six	provided	group	
mean	FEV1(%pred.)	values	(Incalzi	et	al.,	1997;	Liesker	et	al.,	2004;	Ortapamuk	and	Naldoken,	
2006;	Dodd	et	al.,	2013;	Cleutjens	et	al.,	2017;	Spilling	et	al.,	2017).	However,		
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Figure	1:	Search	strategy	flow	chart	
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recently	 revised	 guidelines	 introduced	 the	 inclusion	 of	 self-reported	 symptoms	 and	
exacerbation	history	into	severity	gradings	(GOLD,	2016).	Only	one	study	in	this	review		
reported	 severity	 in	 this	 manner	 (Karakontaki	 et	 al.,	 2013).	 Further	 details	 of	 GOLD	
classification	 systems	 are	 illustrated	 in	 Appendix	 1.4.	 	 The	 overall	 range	 of	 severity	 of	
participants	 in	 this	 review	 covered	 ‘mild’	 to	 ‘very	 severe’.	 One	 study	 analysed	 results	 for	
groups	of	differing	severity	separately	(Ryu	et	al.,	2013).	Three	studies	included	data	only	for	
‘moderate’	to	‘severe’	participants	(Incalzi	et	al.,	1997;	Borson	et	al.,	2008;	Ryu	et	al.,	2013)	
while	one	examined	a	‘severe’	to	‘very	severe’	sample	(Ortapamuk	and	Naldoken,	2006).	The	
remaining	seven	papers	studied	mixed	severity	groups.	
	
In	exploration	of	the	 influence	of	hypoxemia	and	hypercapnia,	eight	studies	provide	mean	
arterial	 blood-gas	 values	 (ABGs)	 (Incalzi	 et	 al.,	 1997;	 Liesker	 et	 al.,	 2004;	Ortapamuk	 and	
Naldoken,	2006;	Zhang	et	al.,	2012;	Dodd	et	al.,	2013;	Karakontaki	et	al.,	2013;	Cleutjens	et	
al.,	2017;	Spilling	et	al.,	2017).	Five	studies	deliberately	controlled	for	ABGs	through	sample	
selection	(Grant	et	al.,	1982;	Incalzi	et	al.,	1997;	Liesker	et	al.,	2004;	Ortapamuk	and	Naldoken,	
2006;	 Karakontaki	 et	 al.,	 2013;	 Spilling	 et	 al.,	 2017)	 and	 one	 of	 these	 studies	 examined	
differences	between	two	groups	classified	by	ABGs	(Ortapamuk	and	Naldoken,	2006).	Five	
studies	included	a	hypoxemic	sample	(Grant	et	al.,	1982;	Incalzi	et	al.,	1997;	Ortapamuk	and	
Naldoken,	2006;	Karakontaki	et	al.,	2013;	Spilling	et	al.,	2017),	while	two	included	hyercapnic	
participants	 (Incalzi	et	al.,	1997;	Ortapamuk	and	Naldoken,	2006).	Five	studies	discuss	 the	
relationship	between	ABGs	and	neuropsychological	performance	(Grant	et	al.,	1982;	Liesker	
et	al.,	2004;	Ortapamuk	and	Naldoken,	2006;	Dodd	et	al.,	2013;	Karakontaki	et	al.,	2013).	
Quality	ratings		
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Two	included	studies	were	rated	as	high	quality	(++)	(Dodd	et	al.,	2013;	Cleutjens	et	al.,	2017),	
with	the	remaining	nine	rated	as	acceptable	(+).	A	summary	of	item-specific	quality	scores	for	
each	 study	 can	 be	 found	 in	 Appendix	 1.5.	 Due	 to	 variations	 in	 study	 design,	
neuropsychological	measures	and	confounding	variables	controlled	for,	it	was	not	possible	to	
systematically	evaluate	whether	study	quality	influenced	overall	findings.	
	
All	studies	had	a	clear	aim	and	confirmed	cases	were	clearly	differentiated	from	controls.	Five	
articles	ensured	 that	 cases	and	 controls	 came	 from	comparable	populations	 (Grant	et	al.,	
1982;	Incalzi	et	al.,	1997;	Liesker	et	al.,	2004;	Dodd	et	al.,	2013;	Cleutjens	et	al.,	2017)	and	six	
ensured	controls	were	non-cases	(Grant	et	al.,	1982;	Ortapamuk	and	Naldoken,	2006;	Dodd	
et	 al.,	 2013;	 Ryu	 et	 al.,	 2013;	 Cleutjens	 et	 al.,	 2017;	 Spilling	 et	 al.,	 2017).	 Seven	 studies	
evidenced	 neuropsychological	 measure	 validity	 and	 reliability	 by	 providing	 appropriate	
evaluations	or	references	(Incalzi	et	al.,	1997;	Ortapamuk	and	Naldoken,	2006;	Borson	et	al.,	
2008;	Zhang	et	al.,	2012;	Dodd	et	al.,	2013;	Karakontaki	et	al.,	2013;	Cleutjens	et	al.,	2017).	
None	of	the	studies	reported	confidence	intervals.		
	
Eight	studies	clearly	stated	that	the	same	exclusion	criteria	were	applied	to	COPD	patients	
and	controls	(Incalzi	et	al.,	1997;	Liesker	et	al.,	2004;	Borson	et	al.,	2008;	Zhang	et	al.,	2012;	
Karakontaki	et	al.,	2013;	Ryu	et	al.,	2013;	Cleutjens	et	al.,	2017;	Spilling	et	al.,	2017).		Articles	
were	considered	to	identify	the	main	potential	confounders	if	they	provided	measures	of,	and	
controlled	for,	the	following	key	variables	in	their	design	or	analysis:	age,	gender,	premorbid-
IQ	or	education,	mental	health	or	mood	and	smoking	status.	Only	one	study	controlled	for	all	
five	variables	(Cleutjens	et	al.,	2017).	All	studies	controlled	for	age	and	gender	and,	with	the	
exception	of	Ryu	et	al.,	 (2013)	and	Spilling	et	al.,	 (2017),	 also	 for	education	or	premorbid	
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intelligence.	Only	two	studies	controlled	for	levels	of	anxiety	and	depression	(Borson	et	al.,	
2008;	Cleutjens	et	al.,	2017),		while	four	studies	controlled	for	smoking	status	(Borson	et	al.,	
2008;	Zhang	et	al.,	2012;	Dodd	et	al.,	2013;	Cleutjens	et	al.,	2017).		
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Table	1:	Summary	of	included	studies	with	sample	characteristics,	neuropsychological	measures	and	quality	ratings	
Study	 Objective	 Sample	size	and	characteristics	 Neuropsychological	
measures		
Results	 Quality	
rating	
Borson	et	al.	
(2008)	
To	examine	the	
pathways	from	
lung	disease	to	
brain	dysfunction	
in	COPD	patients	
and	controls.	To	
construct	a	
testable	model	of	
COPD	and	the	
brain.	
	
n	COPD=	18	
n	Control	=	9	
	
Recruitment	procedures	not	stated.	
	
Classification	of	COPD:	
Moderate	to	severe		
GOLD	stage	(FEV1%pred.):		
{(n1	=	0)	(n2	=	2)	(n3	=8)	(n4	=	7)}	
	
ABGs	not	reported.	
	
Stable	condition	not	further	defined.	
Digit-symbol	coding		
(WAIS-III)	
	
Logical	memory		
(WMS-III)	
	
In	comparison	to	controls,	COPD	patients	
attained	significantly	lower	scores	on	tasks	
examining	processing	speed	and	verbal	
memory.	
	
	
	
	
	
+	
Cleutjens	et	
al.	
(2017)	
To	compare	
general	and	
domain-specific	
cognitive	
impairments	
between	COPD	
patients	and	
controls.	
n	COPD	=	90	
n	Controls	=	90	
	
COPD	participants	were	recruited	via	
pulmonary	rehabilitation.		Controls	were	
recruited	from	the	local	community.	
	
Classification	of	COPD:	
Mixed	disease	severity		
{FEV1%pred.=	54.5	±	23.7}	
	
{PaO2	=	73.5	±	12}	
{PaCO2	=	38.3	±	6.8}	
	
Defined	as	stable	per	GOLD	guidelines:	no	
exacerbation	for	4	weeks.	
Stroop	Colour-Word	Test	
	
Concept-shifting	Test	
	
Letter-digit	Substitution	
	
Visual-verbal	Learning	Task	
	
Digit	Span	(WAIS-III)	
	
Key	Search	(BADS)	
	
Zoo	Map	(BADS)	
Mean	scores	on	tests	examining	processing	
speed,	attention,	memory,	executive	
functions	and	concept	formation	were	
significantly	lower	in	COPD	patients	
compared	to	controls.		
	
In	comparison	to	control	participants	
without	comorbidities	(n	=	43)	COPD	
participants	without	comorbidities	(n=	18)	
attained	significantly	lower	scores	only	in	
tasks	of	abstract	reasoning	and	executive	
function.		
	
In	the	COPD	group,	prevalence	of	clinical	
levels	of	cognitive	impairment	(z	=	<-1SD)	
was	significantly	higher	than	in	the	control	
group	in	the	domains	of	processing	speed,	
memory,	executive	function	and	concept	
formation.		
		
++	
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Study	 Objective	 Sample	size	and	characteristics	 Neuropsychological	
measures	
Results	 Quality	
rating	
Dodd	et	al.	
(2013)	
To	examine	the	
cognitive	abilities	
of	COPD	patients	
when	stable	and	
during	
exacerbation.		
	
	
n	COPD	stable	=	50		
n	COPD	exacerbation	=	30	
n	Controls	=	30	
	
COPD	participants	recruited	via	outpatient	
clinics.	Control	participants	recruited	from	
local	community.		
	
Classification	of	COPD:	
Mixed	disease	severity		
Stable	group:	{FEV1%pred.	=	52	±	22}	
Exacerbating	group:	{FEV1%pred.	=	40±	15}	
	
ABG’s	for	stable	group:	
{PaO2	=	76.5±	13.5}	
{PaCO2	=	37.7	±	3.5}	
Stable:	no	exacerbation	for	8	weeks		
RCFT	
	
Word	lists	(WMS-III)	
	
Verbal	fluency	(DKEFS)	
	
Trails	(DKEFS)	
	
Letter-number	sequencing		
(WAIS-III)	
	
Spatial	span	(WMS-III)	
	
Digit	symbol	(WAIS-III)	
	
Symbol	search	(WAIS-III)	
Stable	COPD	patients	scored	significantly	
lower	than	controls	on	tasks	examining	
processing	speed,	working	memory,	verbal	
memory,	executive	function,	and	
constructional	abilities.		
	
Group	means	for	the	stable	COPD	group	
fell	within	the	‘normal’	range	for	all	tests.	
However,	a	significant	proportion	of	this	
group	had	‘mild’	to	‘moderate’	(z	=	<-1	SD)	
impairment,	particularly	in	measures	
examining	executive	functions,	visual	
memory	and	constructional	performance.		
++	
Grant	et	al.	
(1982)	
To	determine	the	
prevalence,	nature	
and	severity	of	
neuropsychological	
disturbance	in	
hypoxemic	COPD	
patients.		
n	COPD	total	sample	=	203	
n	COPD	subsample	=	51	
n	Controls	=	51	
	
COPD	patients	were	recruited	via	hospital	
clinic	settings	and	private	practice.	Control	
participants	were	well	matched	and	
recruited	from	the	local	community.		
	
Classification	of	COPD:	
Mixed	disease	severity	
Hypoxemic	{PaO2	<60}	
Further	ABGs	not	reported	
Stable:	evidenced	by	consecutive	ABGs	
across	one	week.	
Halsted-Reiten	Battery:		
§ Category	test		
§ Rhythm	test		
§ Speech-sounds	
perception	test		
§ Tactual	performance	
test		
§ Tapping	test		
§ Aphasia	Screening	Test		
§ Trail-making	Test		
§ WAIS	
	
Grooved	pegboard	
	
Short	story	(WMS)	
	
Drawings	(WMS)	
COPD	participants	scored	significantly	
lower	than	controls	in	tasks	examining	
processing	speed,	visual	memory,	concept	
formation,	executive	functions,	perceptual	
and	motor	abilities.	
	
	
+	
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Study	 Objective	 Sample	size	and	characteristics	 Neuropsychological	
measures	
Results	 Quality	
rating	
Incalzi		et	al.	
(1997)	
To	clarify	the	
nature	of	verbal	
memory	
impairment	in	
COPD	and	to	
explore	how	this	
impacts	
medication	
adherence.		
n	COPD	=	42	
n	controls	=	27	
n	AD	=	31	
n	older	controls	=	26	
	
COPD	participants	were	recruited	from	
pneumology	outpatient	clinic.	Age-matched	
and	older	controls	recruited	via	minor	day	
surgery.	AD	participants	recruited	via	
neuropsychology	outpatient	clinic.	
	
Classification	of	COPD:	
Moderate	to	severe		
{FEV1%pred.	=	34	±	9}	
	
Hypoxemic	{PaO2	=	48.8	±	7.6}	
Hypercapnic	{PaCO2	=	56.5	±	7.2}	
	
Stable	condition	not	further	defined.	
RAVLT	
	
Digit	span		
(WAIS-R)	
	
COPD	participants	attained	significantly	
lower	scores	on	some,	but	not	all,	aspects	
of	a	verbal	memory	test	and	on	a	task	of	
working	memory.		
	
Only	38.1%	of	COPD	patients	
demonstrated	a	group-specific	memory	
profile	–	19%	were	classed	as	controls,	
16.7%	as	AD	and	26.2%	as	older	controls.	
	
	
+	
Karakontaki	
et	al.	(2013)	
To	investigate	
whether:	
(a)	cognitive	
performance	was	
impaired	in	COPD	
patients	with	
subclinical	
hypoxemia	
(b)	whether	
cognitive	abilities	
related	to	driving	
ability.	
n	COPD	=	35	
n	controls	=	10	
	
Recruitment	procedures	not	stated.	
	
Classification	of	COPD:	
Mixed	disease	severity	
GOLD	stage	(combined	assessment):		
{(nA	=	4)	(nB	=	7)	(nC	=15)	(nD	=	9)}	
	
Mildly	Hypoxemic	{PaO2	>55}	
{PaO2	=	77±	12}	
{PaCO2	=	41±	6}	
Stable	for	4	weeks	minimum.	
Vienna	Test	System	
§ Reaction	Time	to	Single	
Visual	and	Acoustic	
Stimuli		
§ Selective	Attention	Test		
§ Permanent	Attention	
Test		
§ Tachistoscopic	Traffic	
Test		
	
	
	
	COPD	patients	scored	significantly	lower	
than	controls	tasks	of	processing	speed	
and	perceptual	abilities.		No	significant	
differences	were	identified	in	performance	
on	attention	or	executive	function	tests.		
	
Significantly	less	COPD	participants	than	
controls	were	classed	as	safe	to	drive.	
+	
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Study	 Objective	 Sample	size	and	characteristics	 Neuropsychological	
measures	
Results	 Quality	
rating	
Liesker	et	al.	
(2004)	
To	examine	
cognitive	
performance	in	
non-hypoxemic	
COPD	patients.	
n	COPD	=	30	
n	controls	=	20	
	
COPD	participants	were	recruited	via	
outpatient	clinics.	Control	participants	
recruited	via	an	electronic	database	of	
general	practice.		
	
Classification	of	COPD:		
Mixed	disease	severity	
	{FEV1%pred.	=	49.8±18.7}	
	
Non-hypoxemic	{PaO2	>60}	
{PaO2	=	75.8±8.3}	
{PaCO2	=	39.8±	5.3}	
Stable	according	to	ATS	definition.	
Story	recall		
	
Trail-making		
(Halstead-Reitan)	
	
Stroop	Colour-Word	Task	
	
Digit-symbol		
(WAIS)	
	
Arithmetic		
(Groningen	Intelligence	Test)	
COPD	patients	scored	significantly	lower	
than	controls	in	tasks	examining	
processing	speed.	Significantly	lower	
scores	were	also	identified	in	this	target	
group	in	some,	but	not	all,	measures	of	
executive	functions.	No	significant	
differences	between	the	two	groups	were	
observed	in	performance	on	a	verbal	
memory	task.		
	
	
+	
Ortapamuk	
&	Naldoken	
(2006)	
	
To	explore	
cerebral	perfusion	
patterns	and	
cognitive	
performance	in	
COPD.	
n	COPD	(hypoxemic)	=	8	
n	COPD	(non-hypoxemic)	=	10		
n	Controls	=	10		
	
Recruitment	procedures	not	stated.	
	
Classification	of	COPD:	
Severe	to	very	severe		
{FEV1%pred	=	33.9	±	13}	
	
Hypoxemic	and	hypercapnic		
{PaO2	=	51.6	±	4.1}	
{PaCO2	=	47.6	±	7.9}	
	
Non-hypoxemic	and	normocapnic	{PaO2	=	
67.5	±	4.9}	
{PaCO2	=	39.9	±	5.1}	
Stable	condition	not	further	defined	
Mental	deterioration	battery	
§ RAVLT	
§ Word	fluency	and	
phrase	construction	
§ Raven’s	matrices		
§ Copying	drawings		
§ Temporal	rule	induction	
WMS	-	R	
§ Mental	control	
§ Figural	memory	
§ Logical	memory	I&II	
§ Visual	and	verbal	paired	
associates	I&II	
§ Visual	reproduction	I&II	
§ Digit	span		
§ Visual	memory	span		
Colour-Trail	Test	
Groove	Pegboard		
Compared	to	controls,	hypoxemic	COPD	
patients	scored	significantly	lower	on	tasks	
exploring	memory	and	attention.			Non-
hypoxemic	COPD	patients	only	scored	
significantly	lower	than	controls	on	a	test	
of	verbal	memory.	No	significant	
differences	were	identified	between	either	
COPD	groups	and	controls	on	measures	of		
constructional	abilities,	language,	concept	
formation	or	executive	functions.			
	
	
+	
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Study	 Objective	 Sample	size	and	characteristics	 Neuropsychological	
measures	
Results	 Quality	
rating	
Ryu	et	al.	
(2013)	
To	compare	
regional	
microstructural	
brain	changes	in	
COPD	patients	and	
controls	
n	COPD	=	19	
n	Control	=	12	
	
COPD	participants	were	recruited	via	
hospital	pulmonary	medicine	database.	
Control	participant	recruitment	procedures	
not	stated.		
	
Classification	of	COPD:	
Moderate	n13:	{FEV1%pred.	50-80}		
Severe	n6:	{FEV1%pred.	<50}	
	
ABGs	not	reported.	
	
Stable	condition	not	further	defined.	
Seoul	Neuropsychological	
Battery:		
§ Digit	span	
§ Boston	naming	test	
(Korean)		
§ Written	calculations	
§ RCFT	
§ Seoul	Verbal	Learning	
Test	
§ COWAT	
§ Stroop	Task	
Compared	to	both	controls	and	the	
‘moderate’	COPD	group,	the	‘severe’	COPD	
group	attained	significantly	lower	scores	in	
tasks	of	concept	formation	and	executive	
functions.	
	
	
+	
Spilling	et	
al.	(2017)	
To	examine	
macroscopic	grey	
and	white-matter	
differences	in	
stable	COPD	
patients	with	
subclinical	
cognitive	
impairment.	
n	COPD	=	31		
n	controls	=	24	
	
COPD	participants	were	recruited	via	
outpatient	clinics.	Control	participants	were	
recruited	from	the	local	community.		
	
Classification	of	COPD:	
Mixed	disease	severity	
{mean	FEV1%pred.	=	52.1	±	20.9}		
	
Mildly	Hypoxemic	
{PaO2	=	75.8	±	16.5}	
Normocapnic		
{PaCO2	=	37.5	±	5.3}	
	
Stable	condition	not	further	defined	
	
	
RCFT		
	
Word	lists	(WMS-III)	
	
Verbal	fluency	(DKEFS)	
	
Trails	(DKEFS)	
	
Letter-number	sequencing	
(WAIS-III)	
	
Spatial	span	(WAIS-III)	
	
Digit	symbol	(WAIS-III)	
	
Symbol	search	(WAIS-III)	
In	comparison	to	controls,	COPD	
participants	performed	significantly	lower	
in	tests	examining	processing	speed,	
attention,	memory	and	executive	function.	
	
+	
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Study	 Objective	 Sample	size	and	characteristics	 Neuropsychological	
measures	
Results	 Quality	
rating	
Zhang	et	al.	
(2012)	
To	examine	
whether	there	is	
brain	structural	
alteration	in	COPD.	
n	COPD	=	25	
n	controls	=	25	
	
COPD	participants	were	recruited	via	
inpatient	rehabilitation.	Recruitment	
procedures	for	controls	not	stated.		
	
	
Classification	of	COPD:	
Mixed	disease	severity	
GOLD	stage	(FEV1%pred.):	
{(n1	=	1)	(n2	=	8)	(n3	=7)	(n4	=	9)}	
	
{PaO2	=	79.9	±	23.3}	
{PaCO2	=	48.1	±	6.0}	
	
Stable	condition	not	further	defined.	
Digit	Span		
(WMS-R	Chinese)	
	
Visual	reproduction		
(WMS-R	Chinese)	
	
Figure	memory		
(WMS-R	Chinese)	
COPD	patients	had	significantly	lower	
scores	in	visual	memory	tests	in	
comparison	to	controls.	No	significant	
differences	were	identified	between	the	
groups	on	working	memory	performance.		
	
	
	
+	
Abbreviations:	FEV1%pred.	=	forced	expiratory	volume	in	one	second	(FEV1)	as	a	percentage	of	demographic-predicted	FEV1;	ABGs	=	arterial	
blood	gases;	PaO2	=	Partial	pressure	of	oxygen;	PaCO2	=	Partial	pressure	of	carbon	dioxide;	ATS	=	American	Thoracic	Society;	WMS-R/III	=	
Wechsler	Memory	Scale	various	editions;	WAIS-R/III	=	Wechsler	Adult	Intelligence	Scale	various	editions;		RCFT	=	Rey	Complex	Figure	Test;	
DKEFS	=	Delis-Kaplin	Executive	Function	System;	BADS	=	Behavioural	Assessment	of	Dysexecutive	Syndrome;	COWAT	=	Controlled	Oral	Word	
Association	Test;	RAVLT	=	Rey	Auditory	Verbal	Learning	Test;;	AD	=	Alzheimer’s	Disease.	
Note:	All	ABGs	given	as	mmHg.		
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Table	2:	Domain-specific	difficulties	observed	in	reviewed	studies	
	
	 	
Processing	
Speed	
Attention	
&	
Working	
Memory	
	
Language	
	
Perception	
	
Constructional		
	
Motor	
	
Memory	
Concept	
Formation	
&	Abstract	
Reasoning	
	
Executive	
Functions		
Borson	(2008)	
	 X	 	 	 	 	 	 X	 	 	
Cleutjens	(2017)	
	 X	 X	 	 	 	 	 X	 	 X	
Dodd	(2013)	
	 X	 X	 	 	 X	 	 X	 	 X	
Grant	(1982)	
	 	 	 	 X	 X	 X	 X	 X	 X	
Incalzi	(1997)	
	 	 X	 	 	 	 	 X	 	 	
Karakontaki	(2013)	
	 X	 	 	 X	 	 	 	 	 	
Liesker	(2004)	
	 X	 	 	 	 	 	 	 X	 X	
Ortapamuk	(2006)	
	 	 X	 	 	 	 	 X	 	 	
Ryu	(2013)	
	 	 	 	 	 	 	 	 X	 X	
Spilling	(2017)	
	 X	 X	 	 	 	 	 X	 	 X	
Zhang	(2012)	 	 	 	 	 	 	 X	 	 	
	
									=	assessed,	X	=	difference/impairment	found		
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Summary	of	overall	findings		
Cognitive	performance	
All	studies	included	in	this	review	demonstrated	some	evidence	of	cognitive	dysfunction	in	stable	
COPD	patients.	Table	2	provides	a	summary	of	the	domains	addressed	in	each	study.	Details	of	
domain	classification	of	neuropsychological	tests	can	be	found	in	Appendix	1.6.	COPD	patients	
attained	 significantly	 lower	 scores	 than	 controls	 in	 every	 study	 examining	 processing	 speed	
(Liesker	et	al.,	2004;	Borson	et	al.,	2008;	Dodd	et	al.,	2013;	Karakontaki	et	al.,	2013;	Cleutjens	et	
al.,	2017;	Spilling	et	al.,	2017),	but	only	 in	half	of	 the	 investigations	of	attention	and	working	
memory	(Incalzi	et	al.,	1997;	Ortapamuk	and	Naldoken,	2006;	Dodd	et	al.,	2013;	Cleutjens	et	al.,	
2017;	Spilling	et	al.,	2017).	No	significant	between-group	differences	were	 identified	 in	either	
studies	 assessing	 language	 (Grant	 et	 al.,	 1982;	 Ryu	 et	 al.,	 2013).	 In	 contrast,	 both	 studies	
examining	perceptual	functions	found	significantly	reduced	performance	in	COPD	participants	in	
comparison	to	healthy	volunteers	(Grant	et	al.,	1982;	Karakontaki	et	al.,	2013).		
COPD	participants	scored	significantly	lower	than	controls	in	only	one	of	three	studies	examining	
these	 functions	 (Grant	 et	 al.,	 1982).	 Most	 studies	 investigating	 concept	 formation,	 abstract	
reasoning	and	executive	functions	found	COPD	participants	performed	significantly	lower	than	
controls	(Grant	et	al.,	1982;	Liesker	et	al.,	2004;	Dodd	et	al.,	2013;	Ryu	et	al.,	2013;	Cleutjens	et	
al.,	2017;	Spilling	et	al.,	2017).		
	
Eight	out	of	 ten	papers	assessing	memory	performance	observed	 that	 the	COPD	group	mean	
scores	were	significantly	 lower	than	the	control	group	(Grant	et	al.,	1982;	 Incalzi	et	al.,	1997;	
Ortapamuk	 and	 Naldoken,	 2006;	 Borson	 et	 al.,	 2008;	 Zhang	 et	 al.,	 2012;	 Dodd	 et	 al.,	 2013;	
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Cleutjens	et	al.,	2017;	Spilling	et	al.,	2017).	Distinctions	were	made	between	verbal	and	non-
verbal	 memory	 in	 many	 of	 these	 studies,	 with	 three	 (Incalzi	 et	 al.,	 1997;	 Ortapamuk	 and	
Naldoken,	2006;	Borson	et	al.,	 2008)	and	 two	articles	 (Grant	et	al.,	 1982;	Zhang	et	al.,	 2012)	
illustrating	 significantly	 lower	 scores	 for	 COPD	participants	 in	 verbal	 and	 non-verbal	memory	
tasks	in	comparison	to	controls.	Interestingly,	Incalzi	et	al.	(1997)	compared	the	verbal	memory	
profile	of	COPD	patients	with	aged-matched	healthy,	Alzheimer’s	and	older	healthy	participants.		
This	 analysis	 highlighted	 reduced	 retrieval	 efficiency	 in	 comparison	 to	 age-matched	 controls.	
However,	COPD	patients’	memory	scores	were	significantly	better	than	the	Alzheimer’s	group.		
Discriminant	analysis	 found	only	31%	of	COPD	patients	 conformed	 to	a	 group-specific	profile	
while	26.2%	fell	into	the	older	control	classification.		
	
Conclusions	drawn	from	specific	examination	of	high	quality	studies	(Dodd	et	al.,	2013;	Cleutjens	
et	al.,	2017)	were	in	keeping	with	the	overall	findings	of	this	review.	Each	paper	demonstrated	
significantly	 lower	 scores	 for	 COPD	 patients	 in	 comparison	 to	 controls	 in	 the	 domains	 of	
processing	speed	and	executive	difficulties.	Similarly,	both	studies	highlighted	significantly	lower	
scores	in	in	attention	and	memory	tasks	for	COPD	participants	compared	to	controls,	although	
this	effect	became	non-significant	when	adjusting	for	comorbidities	in	Cleutjens	et	al.	(2017).		
	
Magnitude	of	cognitive	difficulties		
Given	the	variation	in	sample	sizes	of	studies	included	in	this	review,	it	is	possible	that	relatively	
minor	 between	 group	 differences	 may	 have	 reached	 statistical	 significance.	 Furthermore,	
observations	of	significantly	reduced	performance	in	comparison	to	controls	does	not	confirm	
	 29	
cognitive	 impairment	to	the	extent	of	clinical	 thresholds.	Therefore,	to	better	understand	the	
functional	 impact	 of	 any	 cognitive	 difficulties	 in	 this	 disease,	 it	 is	 necessary	 to	 examine	 the	
magnitude	cognitive	difficulties	observed	in	COPD	groups,	either	in	comparison	to	control	groups	
or	 standardised	 norms.	 A	 few	 included	 studies	 made	 some	 investigation	 of	 the	 severity	 of	
cognitive	difficulties.	 	Cleutjens	et	al.	 (2017)	examined	compound	z-scores	across	functions	of	
processing	 speed,	 planning,	 working	memory,	 verbal	memory	 and	 cognitive	 flexibility.	While	
COPD	 patients	 performed	 significantly	 worse	 than	 controls	 on	 these	 measures,	 only	 their	
cognitive	 flexibility	 performance	 reached	 levels	 of	 clinical	 impairment	 (Z-score	 below	 -1SD).	
Another	study	reported	the	proportion	of	different	groups	to	meet	classifications	for	‘moderate	
to	severe’	impairment	(Dodd	et	al.,	2013).	A	substantial	proportion	(>20%)	of	the	COPD	group	
fell	 within	 this	 impaired	 range	 (Z-score	 below	 -1SD)	 on	 subtasks	 examining	memory,	mental	
switching,	 processing	 speed	 and	 visuospatial	 function.	 In	 contrast,	 a	 study	 exploring	 driving-
related	attentional	 performance	 reported	percentiles	 for	COPD	participants	 falling	within	 the	
‘low	 average’	 to	 ‘average’	 range	 (Karakontaki	 et	 al.,	 2013)	 .	 Nevertheless,	 the	 COPD	 group’s	
scores	were	significantly	lower	than	controls.		
	
None	of	the	included	papers	reported	effect	sizes	but	these	were	calculated	where	possible.	Due	
to	data	reporting,	it	was	not	possible	to	calculate	effect	size	for	four	studies	(Grant	et	al.,	1982;	
Liesker	et	al.,	2004;	Karakontaki	et	al.,	2013;	Ryu	et	al.,	2013).	Table	3	summaries	all	effect	sizes	
(Cohen’s	 d)	 for	 between-group	 differences	 on	 individual	 cognitive	 measures.	 Due	 to	 the	
heterogeneity	of	measures	used,	overall	weighted	effect	sizes	were	not	calculated.	Effect	sizes	
of	processing	speed	tasks	ranged	from	0.4	to	1.67	(median	=	0.93),	while	those	of	attention	and	
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working	memory	tests	ranged	from	0.09	to	0.97	(median	=	0.4).		Language	and	construction	task	
effect	sizes	were	small,	respectively	ranging	from	0.11	to	0.4	(median	=	0.25)	and	0.06	to	0.32	
(median	=	0.16).	 It	was	only	possible	to	calculate	one	perception-based	effect	size	which	was	
0.81.	Many	effect	sizes	were	calculated	for	memory	tasks	with	values	covering	a	wide	range	(0.11	
to	1.54,	median	=	0.54).	Similarly,	executive	function	effect	sizes	were	varied,	ranging	from	0.11	
to	1.13	(median	=	0.67).	Effect	sizes	of	concept	formation	and	abstract	reasoning	tasks	ranged	
from	0.02	to	0.78	(median	=	0.46).	
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Table	3:	Summary	of	Individual	Effect	Sizes	for	Cognitive	Measures	in	Studies	
Study	 Cognitive	Test	 Effect	Sizes	
(Cohen’s	d)	
Borson	
	
	
	
	
Digit	symbol		
Logical	memory	
O2-dependent		
COPD	vs	C	
1.67	
1.13	
Non-O2-dependent		
COPD	vs	C	
0.40	
0.52	
	 	 	 	
Cleutjens	
	
	
SCWT	1	
CST	–	A	
LDST	written	
LDST	oral	
Key	search	
Zoo	map	
VVLT	trial	1	
DS	backwards	
VVLT	total	recall	
VVLT	delayed	recall	
VVLT	retention	
SCWT	3	
CST-C	
COPD	vs	C	
0.48	
0.58	
1.00	
0.86	
0.66	
0.67	
0.55	
0.09	
0.68	
0.54	
0.39	
0.85	
0.78	
	
	 	 	 	
Dodd	
	
	
Memory	visual	IR	
Memory	visual	DR	
Memory	verbal	IR	
Memory	verbal	DR	
Trails	
Verbal	fluency	
Working	memory	index	
Processing	speed	index	
Visuospatial	
COPD	vs	C	
0.43	
0.44	
0.73	
0.24	
1.01	
0.25	
0.79	
1.10	
0.81	
	
	 	 	
Incalzi	
	
	
Immediate	recall	
Verbal	learning	
Primacy	
Secondary	memory	
Recency	
Delayed	recall	
Intrusions	
True	positive	recognition	
False	positive	
recognition	
Accuracy	recognition	
Verbal	forgetting	
Retrieval	
DS-forward	
DS-backwards	
COPD	vs	C	
0.97	
0.41	
0.65	
0.93	
0.33	
0.90	
0.45	
0.53	
0.62	
0.77	
0.39	
0.78	
0.33	
0.55	
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Study	 Cognitive	Test	 Effect	Sizes	
(Cohen’s	d)	
Ortapamuk	
	
	
	
Verbal	memory	
Immediate	recall	
Delayed	recall	
Delayed	recognition	
Verbal	fluency	
Word	generation	
Copying	drawings	
Copy	with	landmarks	
DS-forwards	
DS-backwards	
Raven’s	matrices	
Temporal	rule	induction	
Hypoxemic		
COPD	vs	C	
0.18	
1.10	
1.54	
0.36	
0.22	
0.27	
0.10	
0.32	
0.09	
0.48	
0.59	
0.02	
Non-hypoxemic		
COPD	vs	C	
0.11	
0.22	
0.27	
0.30	
0.11	
0.41	
0.06	
0.21	
0.14	
0.21	
0.40	
0.46	
	 	 	 	
Spilling	
	
	
Executive	function	
Episodic	memory	
Processing	speed	
Working	memory	
COPD	vs	C	
1.13	
0.63	
0.93	
0.92	
	
	 	 	 	
Zhang	
	
	
DS-forwards	
DS-backwards	
Visual	reproduction	
Figure	memory	
COPD	vs	C	
0.47	
0.12	
0.66	
0.76	
	
Abbreviations:	C	=	controls;	SCWT	=	Stroop	Colour-Word	Task;	CST	=	Card-Sorting	Task;	IR	=	
immediate	recall;	DR	=	delayed	recall;	Letter-Digit	Substitution	Test,	VVLT	=	Visual	Verbal	
Learning	Task;	DS	=	Digit	Span	
Cohen’s	d	convention:	Small	(d	=	0.2),	Medium	(d	=	0.5),	Large	(d	=	0.8)	
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Relationship	with	disease-related	variables		
Overall,	 most	 studies	 examining	 the	 relationship	 between	 arterial	 blood	 gases	 (ABGs)	 and	
cognition	 indicated	 poorer	 performance	 in	 lower	 oxygen	 levels.	 In	 hypoxemic	 groups,	
significantly	lower	scores	than	controls	were	reported	across	memory,	attention	(Incalzi	et	al.,	
1997;	Ortapamuk	and	Naldoken,	2006),	perceptual,	visuospatial	and	executive	domains	(Grant	
et	al.,	1982).	However,	 in	comparing	non-hypoxemic	groups	and	controls,	 significantly	poorer	
scores	were	also	recorded	in	memory	(Ortapamuk	and	Naldoken,	2006),	processing	speed	and	
executive	 skills	 (Liesker	 et	 al.,	 2004).	 Significant	 correlations	 were	 demonstrated	 between	
neuropsychological	performance	and	partial	pressure	of	oxygen	 in	some	studies	 (Grant	et	al.,	
1982;	Karakontaki	et	al.,	2013).	Although,	circulating	oxygen	levels	did	not	appear	to	correlate	
with	 cognitive	 scores	 in	 a	 group	 of	 non-hypoxemic	 patients,	 despite	 the	 group	 performing	
significantly	poorer	 than	controls	 (Liesker	et	al.,	2004).	The	 impact	of	oxygen	dependence	on	
neuropsychological	 functioning	 was	 unclear	 with	 conflicting	 studies	 reporting	 evidence	 for	
(Borson	et	al.,	2008)	and	against	 (Cleutjens	et	al.,	2017)	 significantly	 reduced	performance	 in	
oxygen-dependent	 patients,	 in	 contrast	 to	 controls.	 The	 relationship	 with	 hypercapnia	 was	
examined	 less	 often	 and	 findings	 are	 unclear.	 Two	 studies	 concluded	PCO2	 levels	made	 little	
difference	to	cognitive	scores	(Grant	et	al.,	1982;	Dodd	et	al.,	2013).	However,	Karakontaki	et	al.,	
(2013)	 identified	 significantly	 longer	 reaction	 times	 in	 hypercapnic	 patients,	 compared	 to	
controls.		
	
Disease	 severity	 seemed	 to	 have	 little	 relationship	 with	 cognitive	 difficulties.	 Two	 studies	
demonstrated	 no	 significant	 association	 between	 overall	 cognitive	 performance	 and	 disease	
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severity	 (Grant	 et	 al.,	 1982;	 Liesker	 et	 al.,	 2004)	 while	 FEV1(%pred.)	 explained	 only	 modest	
variations	in	Dodd	et	al.	(2013).	However,	one	study	identified	significant	correlations	between	
lung	 function,	 reaction	 times	 and	 visuospatial	 abilities	 (Karakontaki	et	 al.,	 2013).	 Similarly,	 in	
distinguishing	 between	 moderate	 and	 severe	 groups,	 another	 paper	 reported	 significantly	
reduced	overall	neuropsychological	performance,	in	comparison	to	controls,	only	for	the	severe	
group	(Ryu	et	al.,	2013).			
	
Relationship	with	other	contributing	factors		
Despite	 the	widely	 evidenced	 influence	 of	mental	 health	 on	 cognitive	 abilities,	many	 studies	
neglected	 this	 potential	 confound.	 For	 example,	 Borson	 et	 al.	 (2008)	 reported	 co-occurring	
significant	differences	in	measures	of	mood	and	cognitive	functioning	yet	did	not	examine	any	
association	 between	 these	 variables.	 In	 a	more	 detailed	 investigation,	 Cleutjens	et	 al.	 (2017)	
reported	 higher	 levels	 of	 anxiety	 and	 depression	 in	 COPD	 participants	 but	 did	 not	 find	 any	
significant	 differences	 in	 cognitive	 performance	 when	 comparing	 COPD	 patients	 above	 and	
below	clinical	thresholds	for	mood.	Similarly,	the	influence	of	smoking	history	was	not	commonly	
addressed.	One	study	suggested	that	smoking	history	may	explain	significant	but	very	modest	
differences	 in	 neuropsychological	 performance	 (Dodd	 et	 al.,	 2013)	 but	 another	 found	 no	
significant	relationship	(Liesker	et	al.,	2004).		
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DISCUSSION	
The	current	review	asked	two	questions:	(1)	What	is	the	nature	of	cognitive	dysfunction	in	stable	
COPD?	(2)	Is	there	a	relationship	between	cognitive	dysfunction	and	condition-specific	variables	
such	as	disease	severity	and	arterial	blood-gases?	Cognitive	difficulties	in	stable	COPD	patients	
were	identified	in	every	study	included	in	this	review,	suggesting	that	COPD	patients	may	be	at	
increased	risk	of	brain	dysfunction	even	in	a	stable	phase	of	their	disease.	Due	to	methodological	
variation,	 it	 is	difficult	 to	 identify	a	particular	“cognitive	profile”	of	stable	COPD.	 	Widespread	
difficulties	 across	 domains	 may	 be	 indicative	 of	 general	 cognitive	 decline	 in	 keeping	 with	
suggested	theories	of	an	accelerated	aging	influence	of	the	disease	(Grant	et	al.,	1982;	Kirkil	et	
al.,	 2007).	 	 Overall,	 significant	 group	 differences	 and	 noteworthy	 effect	 sizes	 were	 most	
consistently	 found	 in	 the	 domains	 of	 processing	 speed,	 concept	 formation	 and	 abstract	
reasoning,	executive	functions	and	memory.	Cognitive	difficulties	seem	to	have	some	association	
with	hypoxemia,	while	hypercapnia	and	disease	severity	appear	to	exert	less	influence.	This	was	
the	 first	 review	 to	 examine	 domain-specific	 cognitive	 abilities	 in	 only	 stable	 COPD	 samples.	
However,	 the	 findings	 of	 the	 current	 study	 are	 in	 keeping	 with	 previous	 reviews	 examining	
general	COPD	samples,	both	in	terms	of	cognitive	domains	affected	and	relationship	with	arterial	
blood	gases	(Hynninen	et	al.,	2005;	Schou	et	al.,	2012;	Torres-Sánchez	et	al.,	2015).			
	
Clinical	implications		
Several	studies	in	this	review	demonstrated	relationships	between	cognitive	performance	and	
functional	 abilities.	 Incalzi	 et	 al	 (1997)	 reported	 significant	 correlations	 between	medication	
compliance	 and	 long-term	memory.	 Similarly,	 co-occurring	 difficulties	 were	 also	 reported	 in	
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cognitive	scores	and	activities	of	daily-living	for	when	comparing	COPD	participants	and	controls	
(Zhang	et	al.,	2012),	although	the	relationship	between	these	abilities	was	not	explored.	COPD	
patients	scored	lower	than	controls	in	five	of	seven	neuropsychological	tests	assessing	driving-
related	performance,	and	were	classified	as	safe	drivers	significantly	less	than	healthy	volunteers	
(Karakontaki	et	al.,	2013).	Furthermore,	health	status	and	quality	of	life	were	found	to	have	a	
significant	positive	association	with	processing	speed	(Liesker	et	al.,	2004).		
	
Examination	of	the	patterns	highlighted	in	this	review	may	inform	recommendations	for	routine	
care	of	stable	COPD	patients.		To	allow	for	slowed	processing	speed,	clinicians	should	be	careful	
to	 provide	 information	 and	 instructions	 at	 an	 appropriate	 speed,	 in	 small	 chunks.	 	 	Memory	
difficulties	 may	 influence	 ability	 to	 recall	 treatment	 schedules	 or	 educational	 information.	
Compensatory	 strategies	 should	 involve	 frequent	 repetitions	 and	 reinforcement	 of	 educative	
material.	Written	guidance	and	use	of	electronic	reminder	systems	may	be	helpful.		Difficulties	
with	executive	skills	may	explain	a	range	of	presentations	commonly	observed	in	COPD	patients	
including	reduced	motivation	or	initiation,	inflexible	behaviour	patterns	or	frequent	preventable	
exacerbations	 (Hall	 and	 Marteau,	 2014).	 Support	 for	 self-monitoring	 and	 decision-making,	
through	 automated-guidance	 telecare	 systems,	 are	 likely	 to	 reduce	 the	 demands	 placed	 on	
patients	to	problem-solve	in	novel	situations.			
	
Methodological	limitations	of	reviewed	studies	
Given	the	purpose	of	this	review,	compliance	with	inclusion	criteria	should	be	carefully	evaluated	
with	particular	emphasis	on	definitions	of	disease	stability.	GOLD,	(2016)	guidelines	state	that	
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patients	should	be	classified	as	in	a	stable	phase	of	the	disease	once	exacerbation-free	for	four	
to	six	weeks.	Only	three	studies	clearly	stated	compliance	with	this	definition	(Liesker	et	al.,	2004;	
Karakontaki	et	al.,	2013;	Cleutjens	et	al.,	2017),	while	Grant	et	al.	(1982)	specified	a	designation	
of	 “stable”	was	 accepted	 after	 one	week	of	 unchanged	ABGs.	 The	 remaining	 articles	 did	 not	
further	 define	 disease	 stability	 and	 thus	 it	 is	 not	 possible	 to	 definitively	 confirm	 all	 included	
samples	met	recognised	classification	criteria.	A	further	limitation	of	this	review	was	the	wide	
range	of	sample	characteristics	of	included	studies.	These	differences	in	methodological	design	
limit	the	strength	of	conclusions	drawn	on	relationships	between	condition	severity,	ABGs	and	
neuropsychological	performance.		
	
Quality	 inspection	 of	 reviewed	 studies	 also	 raises	 some	 concerns	 around	 fulfilment	 of	
appropriate	sample	sizes.	Only	three	studies	referenced	power	calculations	to	justify	sample	sizes	
(Incalzi	 et	 al.,	 1997;	 Dodd	 et	 al.,	 2013;	 Cleutjens	 et	 al.,	 2017).	 Therefore,	 it	 is	 possible	 that	
inconsistencies	in	reported	findings	may	be	partially	explained	by	inadequate	sample	sizes.		More	
detailed	examination	of	effect	sizes	and	patterns	of	significant	findings	would	suggest	that	most	
included	studies	were	sufficiently	powered.	However,	two	studies	with	particularly	small	samples	
reported	few	significant	differences	between	COPD	and	control	groups	performance	(Ortapamuk	
and	Naldoken,	2006;	Ryu	et	al.,	2013).	Similar	results	also	arose	in	an	article	which	appeared	to	
include	skewed	data	 (Liesker	et	al.,	2004).	 It	was	not	possible	 to	calculate	the	effect	sizes	 for	
these	 studies.	 Therefore,	 sufficient	 power	 cannot	 be	 assumed	 and	 the	 findings	 should	 be	
interpreted	in	this	context.		
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Lastly,	critical	consideration	should	be	given	to	the	principles	of	neuropsychological	assessment	
and	 interpretation	 applied	 in	 these	 studies.	 	 Some	 of	 the	 included	 studies	 were	 medically	
oriented,	examining	cognitive	performance	as	a	secondary	outcome	of	interest.	Consequently,	
application	of	neuropsychological	theory	in	these	studies	was	limited.	In	addition,	it	is	important	
to	acknowledge	 that	no	 singular	aspect	of	 cognition	can	be	examined	 in	 isolation.	Therefore,	
performance	on	any	task	thought	to	examine	a	specific	cognitive	function	will	also	be	influenced	
to	 varying	 degrees	 by	 additional	 domains.	 	 A	 wide	 range	 of	 assessment	 measures	 were	
implemented	 across	 included	 studies	 each	 varying	 in	 psychometric	 properties.	 Furthermore,	
adequate	descriptions	or	references	for	these	tests	were	lacking	in	several	studies,	substantially	
reducing	replicability	and	critical	interpretation.	A	range	of	different	scoring	methods	were	also	
implemented	 including	 raw	 and	 scaled	 individual	 subtest	 scores,	 and	 domain-specific	 index	
scores.	 While	 most	 studies	 reported	 group-comparisons	 based	 on	 subtest	 scores,	 others	
examined	frequency	of	clinical	impairment.	Finally,	while	this	review	aimed	to	interpret	all	results	
with	at	a	significance	level	of	p<0.05,	this	was	not	always	possible	due	to	data	reporting	methods.	
Overall,	these	differences	in	neuropsychological	practice	introduce	complex	conceptual	issues	in	
interpretation.		
	
Future	research		
Future	research	should	further	explore	the	influence	of	domain-specific	dysfunction	on	clinical	
outcomes	 such	as	 treatment	adherence,	 attrition	 rates,	quality	of	 life	 and	 independent	 living	
skills.	Continuing	research	into	the	role	of	disease-specific	variables,	including	disease	phase,	is	
also	required	to	develop	greater	understanding	of	biological	pathways	to	brain	dysfunction	and	
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identification	 of	 at-risk	 patients.	 Better	 awareness	 of	 such	 issues	 may	 lead	 to	 targeted	
intervention	studies	to	assess	effectiveness	of	cognitive	rehabilitation	or	assistive	technology	in	
identified	 patient	 groups.	 Although,	 in	 order	 to	 ensure	 validity	 of	 conclusions,	 careful	
consideration	should	be	given	to	the	application	of	neuropsychological	theory	in	this	medically	
driven	 field.	The	 findings	of	 this	 review	promote	 the	potential	benefits	of	neuropsychological	
assessment	 in	 routine	 COPD	 care.	 However,	 assessment	 using	 comprehensive	
neuropsychological	 batteries	 is	 time	and	 resource	 intensive.	 Therefore,	 investigation	 into	 the	
sensitivity	and	specificity	of	brief	cognitive	screening	tools	in	this	population	may	be	required.		
	
	
CONCLUSIONS	
The	findings	of	 this	systematic	review	support	the	notion	that	COPD	patients	may	experience	
some	 degree	 of	 cognitive	 dysfunction,	 even	 in	 a	 stable	 phase	 of	 the	 disease.	 Due	 to	
methodological	variation,	it	was	not	possible	to	identify	a	definitive	cognitive	profile	of	COPD,	
and	patients	were	reported	to	perform	significantly	poorer	 than	controls	across	almost	every	
domain.	However,	deficits	were	demonstrated	most	consistently	in	the	domains	of	processing	
speed,	executive	abilities	and	memory.	Cognitive	dysfunction	in	stable	COPD	patients	seems	to	
worsen	in	hypoxemia	but	the	relationship	with	other	disease-related	variables	is	unclear.	These	
findings	have	may	have	clinical	implications	for	stable	COPD	treatment	guidelines.		
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PLAIN	ENGLISH	SUMMARY		
	
Background:	 Chronic	 Obstructive	 Pulmonary	 Disease	 (COPD)	 is	 an	 umbrella	 term	 for	 several	
conditions	 causing	 progressive	 and	 irreversible	 damage	 to	 the	 airways.	 There	 is	 evidence	 to	
suggest	 that	 COPD	 patients	 may	 experience	 some	 difficulties	 with	 processing	 information	
(cognition).	A	recent	study	explored	attention	in	people	with	COPD	(Klein	et	al.,	2009).		Attention	
is	the	brain’s	way	of	processing	information	which	we	take	in	from	the	environment	through	our	
senses	(for	example,	through	seeing	or	hearing	things).	There	are	different	types	of	attention,	
the	most	well-known	types	are:	how	we	select	information	from	the	environment	to	attend	to;	
and	how	 long	we	can	concentrate	on	something.	Klein	et	al’s	previous	study	used	a	 tool,	 the	
Attention	 Network	 Test	 (Fan	 et	 al.,	 2002),	 which	 was	 developed	 to	 examine	 a	 well-known	
theoretical	model	of	attention	(Petersen	&	Posner,	1990,	2012).	Klein	et	al.	 (2009)	found	that	
COPD	patients	performed	worse	than	controls	on	certain	aspects	of	the	Attention	Network	Test	
but	not	all.	A	limitation	of	Klein	et	al’s	study	was	that	it	only	examined	patients	while	they	were	
staying	 in	hospital	and	were	acutely	unwell.	 There	are	 several	ways	 that	 this	might	 influence	
attention	and	these	participants	would	not	match	the	majority	COPD	patients,	as	most	maintain	
a	relatively	stable	condition	living	in	the	community.	
Objective:	The	current	study	aimed	to	examine	whether	COPD	patients	in	a	stable	phase	of	their	
condition,	differ	in	their	performance	on	attention	tasks	from	healthy	control	participants.		
Methods:		Twenty-three	participants	with	stable	COPD	and	twenty-three	healthy	volunteers	took	
part.		Participants	first	provided	some	demographic	information	and	then	completed	three	tasks	
designed	to	examine	different	components	of	attention.	The	Attention	Network	Task	involved	
looking	 at	 a	 computer	 screen	 and	pressing	 a	 key,	 as	 quickly	 as	 possible,	 to	 indicate	whether	
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arrows	on	the	screen	were	pointing	left	or	right.	This	test	uses	reaction	times	to	examine	three	
different	aspects	of	attention:	alerting,	orienting	and	response	inhibition.	Alerting	is	“achieving	
and	maintaining	an	alert	state”	and	was	measured	by	differences	in	reaction	times	depending	on	
whether	a	warning	cue	was	presented	or	not.	Orienting	 is	“the	selection	of	 information	 from	
sensory	 input”	and	was	 investigated	by	examining	 reaction	 times	when	 the	warning	 cue	was	
presented	 in	 different	 locations.	 Response	 inhibition	 involves	 “resolving	 conflict	 among	
responses,	overcoming	a	strong	automatic	response”.	This	aspect	of	attention	was	measured	by	
presenting	 the	 target	 arrow,	 to	which	 the	 participant	was	 to	 respond,	 accompanied	 by	 four	
flanking	arrows.	Response	inhibition	was	measured	by	comparing	reactions	times	for	when	the	
flanking	arrows	were	pointing	in	the	same	or	different	direction	as	the	target	arrow.	Two	other	
tasks	were	used	 to	examined	 response	 inhibition	 in	different	ways.	 In	one,	participants	were	
asked	to	read	aloud	information	from	a	sheet	of	paper	as	quickly	as	possible.		The	first	part	was	
colour	words	printed	in	black	ink.	The	second	part	was	patches	of	colour.	The	last	part	involved	
participants	stating	the	colour	of	ink	which	colour	words	were	printed	in.	For	example,	the	correct	
response	to	“red”	printed	in	blue	ink	would	be	“blue”.	The	final	measure	of	response	inhibition	
asked	participants	to	first	complete	sentences	with	words	that	made	sense	and	then	words	that	
did	not	fit	sensibly	and	were	completely	unrelated.		
Results:	 The	 people	 with	 stable	 COPD	 who	 were	 included	 in	 this	 study	 had	 more	 difficulty	
maintaining	 alertness	 (alerting)	 and	 suppressing	 a	 natural	 and	 automatic	 response	 (response	
inhibition)	 than	 healthy	 volunteers.	However,	 for	 most,	 these	 difficulties	 were	mild	 and	 not	
statistically	significant.		
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Conclusions:	The	findings	of	this	study	suggest	that	stable	COPD	patients	may	experience	mild	
difficulties	with	some	aspects	of	attention.	For	the	majority	of	these	patients,	such	difficulties	are	
unlikely	to	have	a	substantial	impact	on	their	day-to-day	life	or	ability	to	manage	their	condition.	
However,	 for	 a	 small	 number	 of	 individuals,	 attention	 difficulties	 may	 be	 severe	 enough	 to	
require	additional	support.	Attention	difficulties	seem	to	be	worse	in	COPD	patients	who	are	very	
unwell,	in	comparison	to	those	whose	condition	is	stable.		
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ABSTRACT		
	
Background:	Previous	studies	have	demonstrated	some	attentional	difficulties	in	exacerbating	
COPD	 inpatients.	 However,	 such	 findings	 are	 of	 limited	 clinical	 utility	 and	 raise	 issues	 with	
generalisability	to	the	majority	of	COPD	patients	whose	condition	is	stable.	This	study	aimed	to	
build	on,	and	offer	a	comparison	to,	previous	investigations	by	examining	attention	functions	in	
stable	COPD.		
Methods:	Performance	of	23	stable	COPD	patients	and	23	matched	controls	were	compared	on	
three	 attention-based	 tasks:	 Attention	 Network	 Test,	 Stroop	 Colour-Word	 Task	 and	 Hayling	
Sentence	 Completion	 Task.	 Performance	 on	 these	 tasks	 was	 used	 to	 examine	 alerting	 and	
orienting	attention	and	response	inhibition.		
Results:	No	significant	differences	were	identified	in	between-group	comparisons	of	individual	
subtest	scores.	Inspection	of	between-group	effect	sizes	suggested	a	slight	reduction	in	alerting	
and	response	inhibition	abilities	in	the	COPD	group.	However,	the	study	was	underpowered	to	
detect	effects	at	the	level	observed.	Impairment	analysis	suggested	a	small-subgroup	of	COPD	
participants	 experienced	 response	 inhibition	 difficulties	 beyond	 the	 threshold	 for	 clinical	
impairment.		
Conclusions:	For	most	stable	COPD	patients,	any	attention	difficulties	experienced	are	mild	and	
unlikely	to	have	a	notable	difference	on	everyday	functioning.	However,	a	small	sub-group	may	
be	 at	 risk	 of	 clinically	 relevant	 levels	 of	 attentional	 impairment,	 which	may	 influence	 health	
outcomes.		
Key	words:	Chronic	Obstructive	Pulmonary	Disease;	Neuropsychological;	Attention;	Executive	
Function	
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INTRODUCTION	
	
Chronic	Obstructive	Pulmonary	Disease	(COPD)	is	a	progressive	respiratory	condition,	regarded	
as	a	leading	cause	of	disability	worldwide	(Global	Initiative	for	Chronic	Obstructive	Lung	Disease	
(GOLD),	 2016).	 Airflow	 limitation	 to	 the	 lungs,	 causing	 breathlessness,	 typically	 results	 from	
inflammatory	responses	to	noxious	environmental	particles	or	smoking.	However,	the	impact	of	
this	 disease	may	not	 be	 limited	only	 to	 pulmonary	 problems.	 Recent	 literature	 has	 aimed	 to	
examine	the	many	factors	influencing	the	development,	progression,	management	and	prognosis	
of	this	disease.		
	
One	 thread	 of	 investigation	 has	 identified	 increasing	 evidence	 that	 people	 with	 COPD	 may	
experience	some	degree	of	cognitive	dysfunction	(Hynninen	et	al.,	2005;	Dodd,	Getov	and	Jones,	
2010;	Cleutjens	et	al.,	 2014;	 Lahousse	et	al.,	 2015;	Torres-Sánchez	et	al.,	 2015).	 To	date,	 the	
prevalence	of	cognitive	difficulties	 in	this	group	remains	unclear,	with	estimates	ranging	from	
3.9%	(Chang	et	al.,	2012)	to	77%	(Grant	et	al.,	1982).	Cognitive	dysfunction	has	been	reported	
across	multiple	domains	and,	as	such,	a	disease-specific	cognitive	profile	has	yet	to	be	identified.	
Nonetheless,	cognitive	difficulties	arising	in	this	condition	may	have	substantial	impact	on	clinical	
outcomes	such	as	activities	of	daily	living	(Perneczky	et	al.,	2006)	and	quality	of	life	(Roncero	et	
al.,	 2016).	 Furthermore,	 poor	 medication	 adherence	 (Incalzi	 et	 al.,	 1997)	 and	 impaired	 self-
management	abilities	(Allen	et	al.,	2003)	may	lead	to	frequent	exacerbations,	hospital	admissions	
and	reliance	on	care.		
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The	challenges	to	understanding	cognitive	difficulties	 in	COPD	arise	through	the	multifactorial	
nature	 of	 the	 condition.	 Several	 studies	 have	 explored	 the	 pathology	 underlying	 this	 issue	
(Borson	 et	 al.,	 2008;	 Dodd,	 Getov	 and	 Jones,	 2010;	 Cleutjens	 et	 al.,	 2014).	 Primary	 disease	
presentation	of	reduced	lung	function	often	leads	to	circulating	blood-gas	imbalance.	Evidence	
suggests	that	hypoxemia,	and	to	a	lesser	extent	hypercapnia,	may	have	a	role	in	mediating	brain	
dysfunction	in	COPD	(Stuss	et	al.,	1997;	Ortapamuk	and	Naldoken,	2006).	Hypoxemia	has	been	
associated	 with	 localised	 reductions	 in	 cerebral	 perfusion,	 metabolic	 activity	 and	
neurotransmitter	production	(Grant	et	al.,	1982;	Incalzi	et	al.,	2003;	Ortapamuk	and	Naldoken,	
2006).	Inflammatory	cytokines	and	oxidative	stress	are	also	suggested	to	cause	systemic	changes	
which	may	influence	brain	function	in	this	disease	(Borson	et	al.,	2008).			
	
Increasing	severity	of	COPD	has	been	inconsistently	linked	with	worsening	cognitive	difficulties	
(Schou	et	al.,	 2012).	 Interpretation	of	 these	 findings	 is	 complicated	by	 short-term	changes	 in	
symptoms.		Although	most	COPD	patients	maintain	long	periods	of	a	relatively	stable	condition,	
exacerbations	 are	 common.	 GOLD	 (2016)	 define	 an	 exacerbation	 as	 an	 “acute	 event	
characterised	by	a	worsening	of	symptoms	beyond	normal	day-to-day	variations”.	Recent	studies	
have	suggested	that,	in	comparison	to	those	in	a	stable	phase,	exacerbating	patients	experience	
significantly	more	cognitive	difficulties	(Dodd	et	al.,	2013;	López-Torres	et	al.,	2016).		However,	
due	to	a	lack	of	prospective	studies,	it	is	currently	unclear	whether	these	cognitive	changes	are	
transient	or	continue	post-exacerbation.		Co-morbidities	are	also	the	norm	in	COPD.	Patients	with	
the	disease	often	present	with	co-existing	cardiovascular	disease,	diabetes,	stroke	(Feary	et	al.,	
2010),	anxiety	or	depression	(Hynninen	et	al.,	2005),	each	of	which	may	exert	an	independent	
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influence	 on	 cognitive	 function.	 To	 adequately	 examine	 brain	 function	 in	 this	 condition	 it	 is	
important	 to	 include	 consideration	 of	 these	 disease-related	 variables	 and	 comorbidities	 into	
research	design.		
	
Given	 the	 complex	 pathology	 of	 this	 disease	 is	 dominated	 by	 reduced	 circulating	 oxygen,	
cognitive	 impairment	 may	 be	 expected	 to	 arise	 through	 damage	 or	 dysfunction	 of	 oxygen-
sensitive	neuroanatomical	regions,	namely	the	hippocampus,	basal	ganglia	and	frontal	cerebral	
cortex	 (Paola	et	al.,	 2008).	 In	 keeping	with	 this	 theory,	 difficulties	have	been	 identified	most	
consistently	in	the	cognitive	domains	of	attention	(Klein	et	al.,	2009;	Dodd	et	al.,	2013;	Spilling	et	
al.,	2017),	memory	(Fioravanti	et	al.,	1995;	Incalzi	et	al.	1997),	processing	speed	(Liesker	et	al.,	
2004;	Borson	et	al.,	2008;	Dodd	et	al.,	2013;	Cleutjens	et	al.,	2017)	and	executive	functions	(Incalzi	
et	 al.,	 2003;	 Dodd	 et	 al.,	 2015;	 Cleutjens	 et	 al.,	 2017;	 Spilling	 et	 al.,	 2017).	 However,	 many	
medically-oriented	studies	reporting	on	cognitive	 function	have	examined	this	as	a	secondary	
outcome	 of	 interest.	 These	 investigations	 have	 lacked	 a	 theoretically	 driven	 approach	 to	
neuropsychological	investigation	and	findings	have	often	been	inappropriately	generalised.		
	
In	an	 investigation	of	COPD	 inpatients,	Klein	et	al.	 (2009)	utilised	 the	Attention	Network	Test	
(ANT)	 (Fan	 et	 al.,	 2002)	 to	 examine	 functioning	 of	 distinct	 attention	 systems	 proposed	 by	
Peterson	and	Posner	(1990,	2012).	Neuropsychological	definitions	of	attention	vary;	however,	
this	function	is	broadly	viewed	as	the	processing	of	information	or	stimuli	from	the	environment	
(Lezak	 et	 al.,	 2012).	 The	 ANT	 examines	 three	 different	 attention-based	 functions:	 alerting	
“achieving	and	maintaining	an	alert	state”;	orienting	“the	selection	of	information	from	sensory	
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input”	otherwise	known	as	selective	attention;	and	executive	control	“resolving	conflict	among	
responses,	overcoming	a	strong	habitual,	pre-potent	response”	also	termed	response	inhibition.	
This	previous	study	highlighted	prolonged	reaction	times	and	significantly	reduced	alerting	and	
orienting	effects	in	COPD	patients	compared	to	controls.	Despite	this,	no	significant	differences	
in	 the	 executive	 attention	 function	of	 response	 inhibition	were	 identified.	 These	 findings	 are	
similar	to	the	intact	response	inhibition	observed	in	a	previous	study	examining	Stroop	Colour-
Word	Task	(SCWT)	performance	in	stable	COPD	patients	(Liesker	et	al.,	2004).	However,	a	more	
robust	study,	also	utilising	the	SCWT,	identified	contrasting	results	(Cleutjens	et	al.,	2017).		
	
Klein	et	al's	 (2009)	 study	 limited	 recruitment	of	COPD	participants	 to	 individuals	 admitted	 to	
hospital	 during	 exacerbation.	 All	 task	 procedures	 were	 completed	 during	 the	 inpatient	 stay,	
when	patients	were	medically	unstable.	Such	sample	selection	introduces	multiple	physiological	
confounds	 which	 may	 have	 influenced	 cognitive	 performance.	 Furthermore,	 the	 conclusions	
drawn	 from	 inpatient	 studies	cannot	be	generalised	 to	 the	stable,	 community	dwelling	COPD	
patients	who	make	up	the	majority	of	the	population.	Therefore,	the	current	study	aimed	to	build	
on	the	theoretically	driven	approach	taken	by	Klein	et	al.	(2009)	to	examine	attention	functions	
in	a	group	of	clearly	defined	stable	COPD	patients	and	healthy	age-matched	controls.	This	study	
offers	a	useful	comparison	to	existing	literature	by	examining	alertness,	orienting	and	response	
inhibition	 (conflict)	 using	 the	ANT.	Given	 the	 findings	of	 Klein	et	 al.	 (2009),	 use	of	 additional	
measures	of	response	inhibition,	namely	the	SCWT	and	Hayling	Sentence	Completion	task	(HSCT),	
provide	further	exploration	of	this	function.		
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Hypotheses	
1. Performance	 on	 attention	 tasks	 will	 be	 significantly	 reduced	 in	 COPD	 patients,	 in	
comparison	to	controls.		
a. On	 the	 attention	 network	 test,	 COPD	 patients	 will	 show	 significantly	 reduced	
alerting	 and	 orienting	 effects	 in	 comparison	 to	 controls	 and	 will	 experience	 a	
greater	detrimental	 influence	of	conflicting	stimuli	on	 reaction	 times	 (response	
inhibition)		
b. Compared	to	controls	COPD	patients	will	attain	significantly	lower	scores	on	other	
measures	of	response	inhibition	(HSCT	and	SCWT).	
2. Attention	task	performance	will	negatively	correlate	with	increasing	age,	disease	severity,	
smoking	history	and	levels	of	anxiety	and	depression.	
	
	 	
	 57	
METHODS	
	
Ethical	Approval	
Ethical	approval	for	this	study	was	granted	by	South	Birmingham	NRES	Committee	[Appendices	
2.2	&	2.3].	NHS	Highland	and	NHS	Forth	Valley	Research	and	Development	Departments	granted	
management	approval	[Appendices	2.4	-	2.6].		Participation	in	the	study	was	voluntary	and	all	
participants	provided	written	informed	consent.	
	
Participants		
Twenty-three	COPD	patients	were	recruited	via	respiratory	care	teams,	in	NHS	Highland	and	NHS	
Forth	Valley,	 during	 attendance	 at	 pulmonary	 rehabilitation	 or	 routine	 review	 appointments.		
Inclusion	 criteria	 for	COPD	participants	were:	 (i)	 a	diagnosis	of	COPD,	 (ii)	 COPD	 is	 considered	
clinically	stable	in	accordance	with	GOLD	(2016)	guidelines	(i.e.	exacerbation-free	for	6	weeks).		
Twenty-three	 control	 participants	 were	 recruited	 as	 a	 convenience	 sample	 from	 the	 local	
community.	 	 All	 participants	were	 one-to-one	matched	 for	 age	 and,	where	 possible,	 gender.		
Exclusion	 criteria	 for	 all	 participants	 were:	 (i)	 history	 of	 neurological	 illness	 or	 event	 (e.g.	
dementia,	 multiple	 sclerosis,	 stroke);	 (ii)	 significant	 sensory	 impairment	 or	 co-morbid	 health	
conditions	which	may	affect	participation	 (e.g.	 visual	 or	hearing	 impairment	or	 severe	motor	
impairment);	(iii)	diagnosis	of	major	psychiatric	disorder;	(iv)	non-native	English	speaker.		
	
Justification	of	sample	size	
In	their	examination	of	COPD	inpatients,	Klein	et	al.	(2009)	found	medium	effect	sizes	in	alerting	
and	orienting	effects	(d	=	0.48-0.61).	However,	Cleutjens	et	al.	(2017)	identified	an	effect	size	of	
d=0.85	 on	 differences	 between	 stable	 COPD	 patients	 and	 controls	 in	 SCWT	 performance.	
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Consideration	was	given	to	recruitment	feasibility	and	methodological	differences	within	these	
previous	investigations.	Final	sample	size	estimation	was	based	on	and	the	findings	of	Cleutjens	
et	al.	(2017),	as	this	sample	closely	fitted	the	population	of	interest	in	the	current	study.	Using	
G*power	with	power	set	at	0.8,	alpha	at	0.05	(two	tailed)	d	=	0.85,	a	minimum	of	23	participants	
per	group	was	required.	Taking	a	more	conservative	approach,	the	target	sample	size	was	30	per	
group.		
	
Design	
A	 between-subjects	 design	 was	 used	 to	 examine	 differences	 in	 attention	 functions	 between	
COPD	and	control	participants.	A	within-subjects	design	was	used	 to	examine	 the	association	
between	attention	performance	and:	age;	education;	smoking	pack-years;	anxiety;	depression;	
years	since	diagnosis;	lung-function	and	MRC	score.	
	
Procedure		
COPD	participants	were	recruited	by	respiratory	clinicians	during	routine	contact.	Screening,	to	
ensure	participants	fit	study	criteria,	was	 initially	conducted	by	respiratory	clinicians	and	later	
confirmed	by	the	researcher.	Control	participants	contacted	the	researcher	using	contact	details	
on	a	poster	and	were	screened	at	this	point.	A	single	participation	appointment	was	held	in	an	
NHS	 clinic	 room	 or	 as	 a	 home	 visit.	 Prior	 to	 participation,	 all	 participants	 provided	 written	
informed	consent,	including	granting	access	to	most	recent	spirometry	results	for	COPD	patients	
[Appendices	 2.7-2.10].	 Spirometry	 data	 were	 collected	 from	 respiratory	 clinicians	 post-
participation.		
	
	 59	
Demographic	 information	was	 collected	 for	 all	 participants	 (gender,	 age,	 education,	 smoking	
history	and	health	information).	Additionally,	COPD	participants	provided	information	on	years	
of	 illness	 and	 current	 treatment.	 COPD	 patients	 also	 provided	 ratings	 of	 breathlessness	 and	
impact	 on	 function	 on	 a	 commonly	 used	 self-report	measure,	 the	Medical	 Research	 Council	
(MRC)	 Breathlessness	 Scale	 (Fletcher,	 1960)	 [Appendix	 2.12].	 Subsequently	 all	 participants	
completed	the	Hospital	Anxiety	and	Depression	Scale	(HADS)	(Zigmond	and	Snaith,	1983).	This	
self-report	measure	was	 designed	 for	 use	with	 non-psychiatric	 hospital	 patients.	 It	 has	 good	
reliability	and	validity	with	internal	consistency	of	0.8,	concurrent	validity	of	0.6–0.8	and	both	
specificity	and	sensitivity	of	0.8	(Bjelland	et	al.,	2002).		
	
All	participants	then	performed	three	neuropsychological	tests	as	described	below:		
	
Attention	Network	Test	(ANT)	(Fan	et	al.,	2002)	
The	 ANT	 is	 a	 computer-based	 choice	 reaction	 time	 (RT)	 task	 developed	 to	 examine	 phasic	
alertness,	 spatial	 selective	attention	and	 response	 inhibition.	Through	pressing	corresponding	
buttons	on	a	computer	keyboard,	participants	were	required	to	indicate	whether	a	central	arrow,	
presented	on	a	screen,	pointed	left	or	right.		The	stimuli	(one	central	arrow	or	one	central	arrow	
accompanied	 by	 four	 flanking	 arrows)	 appeared	 either	 above	 or	 below	 a	 fixation	 point.	 The	
arrows	were	presented	under	several	different	conditions	to	manipulate	alerting,	orienting	and	
executive	factors.		There	were	four	warning	conditions	(asterisk	cues)	indicating	the	imminent	
appearance	of	the	target:	(a)	no	cue	(only	fixation	cross),	(b)	centre	cue,	(c)	double	cue,	and	(d)	
spatial	cue.	The	alerting	effect	is	calculated	by	subtracting	double	cue	mean	RT	from	no	cue	mean	
RT.	The	orienting	effect	is	calculated	by	subtracting	spatial	cue	mean	RT	from	centre	cue	mean	
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RT.		To	influence	level	of	conflict,	a	central	target	arrow	was	presented	with	flanker	arrows	which	
were	congruent	or	incongruent	with	the	target	arrow	direction.		The	conflict	effect	is	calculated	
by	subtracting	congruent	mean	RT	from	incongruent	mean	RT.	The	ANT	includes	a	practice	block	
of	24	trials	and	three	assessment	blocks	totalling	288	trials.	Immediate	feedback	is	given	in	the	
practice	block	 (correct,	 incorrect,	 no	 response)	but	not	 in	 the	 assessment	blocks.	 For	 further	
details	of	ANT	instruction	and	stimuli	see	Appendices	2.13	and	2.14.	
	
Hayling	Sentence	Completion	Test	(HSCT)	(Burgess	and	Shallice,	1996)		
As	with	the	conflict	component	of	the	ANT,	the	HSCT	aims	to	detect	difficulties	with	response	
inhibition.	 It	 is	 commonly	 used	 in	 neuropsychological	 evaluation	 and	 is	 composed	 of	 two	
sections.	The	first	section	asks	the	participant	to	complete	a	series	of	sentences	with	a	sensible,	
meaningful	word.	The	participant	is	then	required	to	complete	a	second	series	of	sentences	with	
an	 irrelevant	word	 that	 does	 not	 “fit”	 sensibly	 in	 the	 sentence	 and	 is	 completely	 unrelated.		
Performance	scores	are	calculated	based	on	response	time	and	errors	made.	The	HSCT	has	been	
found	to	have	good	test-retest	reliability	(r=0.72–0.93),	and	internal	consistency	(α=0.62–0.76),	
in	a	range	of	patients	with	neurological	disorders	(Burgess	and	Shallice,	1996).	
	
Stroop	Colour-Word	Task	(SCWT)	(Golden	and	Freshwater,	2002)	
The	SCWT	is	another	measure	of	response	inhibition.	There	are	several	variations	of	the	Stroop	
task	available.	The	version	used	in	this	study	is	the	most	commonly	used	English	language	format,	
which	has	 three	parts.	 In	 the	 first	 section	participants	 are	 asked	 to	 read	 aloud,	 as	 quickly	 as	
possible,	a	page	of	colour-words	(red,	blue	or	green)	which	are	printed	in	black	ink.	In	the	second	
section,	participants	are	asked	to	 identify	patches	of	colours.	Lastly,	participants	are	asked	to	
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state	the	colour	of	ink	in	which	the	colour-word	is	printed,	the	ink	being	a	different	colour	to	the	
word	itself	e.g.	the	correct	response	to	the	word	“red”	printed	in	blue	ink	would	be	“blue”.	There	
is	a	45	second	time	limit	for	each	section.	Number	of	correct	responses	provided	is	taken	as	the	
raw	 score.	An	 interference	 scores	 is	 calculated	by	 subtracting	a	predicted	 colour-word	 score,	
based	on	performance	in	the	first	two	sections,	from	the	observed	colour-word	score.		The	SCWT	
has	been	 found	 to	have	good	 test-retest	 reliability	 (r=0.73-0.89)	 (Golden,	1975)	and	a	 similar	
version	of	this	measure	has	been	shown	to	be	sensitive	to	response	inhibition	difficulties	in	COPD	
patients	(Cleutjens	et	al.,	2017).	
	
Data	Analysis	
Distribution	of	all	variables	were	examined	to	assess	normality	and	descriptive	statistics	were	
calculated.		For	each	participant	ANT	data	was	pre-processed	in	line	with	Klein	et	al.	(2009)	to	
exclude	 invalid	 or	 outlier	 trials,	 further	 details	 are	 available	 in	 Appendix	 2.16.	 	 To	 compare	
variables	 between	 groups,	 independent-t	 tests	 or	 Mann-Whitney	 U	 tests	 were	 utilised	 as	
appropriate.		Effect	sizes	were	reported	as	Cohen’s	d.	Impairment	analysis	for	HSCT	and	SCWT	
was	conducted	in	relation	to	published	test	norms.	As	no	normative	data	was	available	for	the	
ANT,	impairment	classifications	were	based	on	deviations	from	control	group	means.		Cut	offs	
for	clinical	impairment	were	as	follows:	HSCT	(scaled	score	≤	3);	SCWT	mild	(T	<	40),	moderate	(T	
<	30);	ANT	Accuracy	(<90%);	ANT	overall	RT	and	conflict	effect,	mild	(>1SD),	moderate	(>2SD)	
above	 control	mean;	ANT	alerting	and	orienting	mild	 (>1SD),	moderate	 (>2SD)	below	control	
mean.	 	 Chi-square	 analysis	 was	 conducted	 to	 examine	 between-group	 frequency	 of	 clinical	
impairment.	Correlational	analysis	was	exploratory	and	corrections	were	not	made	for	multiple	
	 62	
comparisons.	Due	to	heterogeneity	in	variable	distributions	Spearman	correlations	coefficients	
were	used	to	examine	relationships	between	task	performance	and	participant	characteristics.	
Statistical	significance	was	accepted	at	p<0.05.	
	
RESULTS	
	
Descriptive	Characteristics	
Data	 were	 collected	 for	 23	 COPD	 and	 23	 control	 participants.	 Demographic	 and	 clinical	
characteristics	of	each	group	are	outlined	in	Table	1.	 	There	were	no	significant	differences	in	
gender	x2	=	0.093,	age	(t(df	44)	=	-0.136),	years	of	education	(t(df	44)	=	-1.719),	or	levels	of	anxiety	
(z	=	-0.875)	between	the	groups.		More	COPD	participants	had	a	history	of	smoking,	and	the	COPD	
group	reported	significantly	more	smoking	pack-years	(number	of	packs	per	day	x	years	smoking)	
(z	=	-5.176).		Significant	between-group	differences	were	also	identified	in	levels	of	depression	(z	
=	-2.722),	with	COPD	participants	self-reporting	more	depressive	symptoms	on	the	HADS.		
	
Regarding	disease	status	of	COPD	patients,	median	number	of	years	since	diagnosis	was	six	(IQR	
3	–	15).	Multiple	measures	of	disease	severity	were	recorded.	Mean	FEV1(%predicted)	for	these	
individuals	was	55.0	±	23.	Severity	classifications	of	airflow	restriction	(GOLD	1-4),	MRC	score	(1-
4)	and	combined	severity	grade	(GOLD	A-D)	are	also	displayed	in	the	table.	Additional	details	for	
these	classification	systems	can	be	found	in	Appendix	2.17.	Overall,	most	COPD	participants	fell	
within	the	‘moderate’	to	‘severe’	range	of	disease	severity.	The	majority	of	COPD	participants	
were	 on	 a	 treatment	 regimen	 of	 long-acting	 bronchodilators,	 inhaled	 corticosteroids	 and	
anticholinergics.		Only	three	participants	required	long-term	oxygen	therapy.	
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Table	1:	Participant	Demographic	and	Clinical	Information	
	 															COPD	Participants											
	(n	=	23)	
Control	Participants	
(n	=	23)	
P	value		
Age	 68.9	±	8.2	 69.2	±	9.1	 0.892	
Gender		
							Female	
								Male				
	
15	
8	
	
14	
9	
0.760	
Years	of	Education		 13.1	±	3.0	 14.7	±	3.3	 0.093	
Smoking	status	&	history	
								Never	
								Former	
								Current		
	
1	(4.3%)	
21(91.3%)	
1	(4.3%)	
	
12	(52.2%)	
11	(47.8%)	
0	(0%)	
	
0.006*	
		Smoking	pack	years	 37.5	[28.0	-	45.5]	 0.10	[0.0	-	9.0]	 <0.001*	
HADS		
								Anxiety	
								Depression	
	
6[3	-	7]	
4	[3	-	9]	
	
5[3	-	6]	
2[1	-	4]	
	
0.382	
0.006*	
DISEASE	SEVERITY	(COPD	only	n	=	23)	
Lung	function		 	Self-reported	breathlessness	(MRC	score)	
FEV1(%predicted)							55.5	±	23.0	
	
																	GOLD	Classification		
																			1	(Mild)																						1	
																			2	(Moderate)												12	
																			3	(Severe)																		7	
																			4	(Very	Severe)									3	
	
																					1	
																					2	
																					3	
																					4	
	
2	
7	
6	
8	
	
	 GOLD	combined	severity	classification		
(Lung	function	&	MRC)	
	
	
	 								A				
											B				
					C		
														D	
	2	
11	
	0	
10	
	
				MEDICATION		
(%	of	group	receiving	therapy)	
Long-term	oxygen	therapy	
Long-term	anticholinergics	
Systemic	Corticosteroids	
Inhaled	Corticosteroids	(ICS)	
Short-term	Bronchodilators	
13	
65	
17	
13	
78	
Long-term	beta-2-agonists	(LABA)	
Combination	compound	(ICS	+	LABA)	
Theophylline	
Mucolytic	
Leukotriene	antagonist	
28	
70	
9	
22	
9	
Note:	values	are	mean	±	standard	deviation,	median	[lower-upper	interquartile	range]	or	n.	
p	values	for	Gender	and	Smoking	Status	were	computed	using	chi-square	and	yates’	chi	square	
respectively.	*statistically	significant	difference	between	COPD	and	control	participants.	
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Group	Comparisons	of	Attention	Task	Performance	
Table	2	summarises	between-group	comparisons	of	attention	task	performance.	Although	COPD	
participants	 generally	 performed	 poorer	 on	 most	 measures	 of	 attention,	 none	 of	 these	
differences	 reached	 statistically	 significance.	 Notably,	 the	 COPD	 group	 scores	 covered	 larger	
ranges	in	the	SCWT,	HSCT	and	ANT	RTs.	All	effect	sizes	fell	within	the	small	to	medium	range.	
Largest	effect	sizes,	indicating	reduced	performance	in	the	COPD	group	compared	to	controls,	
were	identified	in	alerting	(d	=	-0.52),	raw	total	HSCT	scores	(d	=	-0.49)	and	SCWT	(d=	-0.44).		
	
Table	3	details	the	frequency	of	clinical	levels	of	impairments	identified	in	each	group.		Chi-square	
analysis	indicated	significantly	more	COPD	participants	were	observed	as	having	mild	impairment	
on	the	SCWT.	No	other	significant	differences	were	noted	and	comparable	proportions	of	each	
group	were	 impaired	across	 the	majority	of	 remaining	measures.	 For	both	COPD	and	control	
groups,	several	participants	demonstrated	response	inhibition	errors	suggestive	of	impairment	
on	the	HCST.		More	COPD	participants	than	controls	were	considered	impaired	on	ANT	accuracy,	
alerting	and	conflict,	although	it	is	unclear	whether	these	findings	are	clinically	important.		
	
	
	
	
	 	
	 65	
Table	2:	COPD	and	control	performance	on	attention	tasks	
	 COPD	
(n	=	23)	
Control	
(n	=	23)	
p-value		 Effect	size	
(95%	confidence	
interval)	
SCWT	
Colour-Word	
Interference	(T	score)a	
	
43.7	±	9.8	
	
47.3	±	5.7	
	
0.144	
	
	
-0.44	
	(-1.03	to	0.14)	
	 	 	 	 	
HSCT	
Time	1	SSa	
	
5.96	±	0.56	
	
	
6.13	±	0.55	
	
	
0.294	
	
	
-0.31	
(-0.89	to	0.28)	
	
Time	2	SSa	 6.13	±	0.55	 6.17	±	0.78	 0.828	 -0.06	
(-0.64	to	0.52)	
	
Converted	Errors	SSb	 6	[2-8]	 7	[6	-	7]	 0.360	 -0.27	
Total	(sum	of	SS)b	 18	[15	-	20]	 19	[18	-	20]	 0.103	
	
-0.49	
	
Total	SSb	 6	[5	-	7]	 6	[6	-	7]	 0.251	
	
-0.34	
	
ANT	
Overall	RT(ms)a		
	
769.6	±	102.1	
	
757.0	±	86.9	
	
0.654	
	
	
0.13	
(-0.45	to	0.71)	
Overall	Accuracy	(%)b	 98.6	[96.5	–	99.3]	 99.0	[94.8	–	99.7]	 0.732	
	
-0.10	
	
	 	 	 	 	
Relative	Alertinga			 2.98	±	4.7	 5.41	±	4.6	 0.084	
	
-0.52		
(-1.11	to	0.07)	
								No	cue	(ms)	 785.9	±	98.9	 780.2	±	89.2	 	 	
								Double	cue	(ms)	 764.2	±106.3	 739.6	±	89.8		 	 	
	 	 	 	 	
Relative	Orientinga	 5.85	±	4.4	 6.3	±	5.2	 0.778	
	
-0.09		
(-0.67	to	0.49)	
							Centre	cue	(ms)	 771.7	±	96.2	 763.1	±	93.0	 	 	
							Spatial	cue	(ms)	 728.7	±	110.0	 714.6±	80.4	 	 	
	 	 	 	 	
Relative	Conflictb		 21.0	[17.8	–	24.5]	 19.6	[17.4	–	23.8]	 0.448	 -0.22	
	
							Incongruent	(ms)	 897	[851	–	1014]	 874	[811	–	967]	 	 	
							Congruent	(ms)	 745.3	[702	-	795]	 718	[687	-	811]	 	 	
Note:	values	are	mean	±	standard	deviation,	median	[lower-upper	interquartile	range].	
Abbreviations:	SS	=	scaled	score;	RT	=	reaction	time	
Effect	size	given	as	Cohen’s	d.	Confidence	intervals	provided	for	normally	distributed	data.		
a	=	t-test;	b	=	Mann-Whitney	U.		
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Table	3:	Frequency	of	clinical	impairment		
	 COPD	
(n	=	23)	
Control	
(n	=	23)	
P	value	 Chi-square	
SCWT	
							Mild		
	
8	(34.8)	
	
2(8.7)	
	
0.032*	
	
4.600	
							Moderate		
	
1(4.3)	 0	(0.0)	 1.000†	 0.000	
HSCT	Errors	 8(34.8)	 5(21.7)	 0.326	 0.965	
HSCT	Total	
	
	
0(0.0)	 1(4.3)	 1.000†	 0.000	
ANT	Accuracy	(<90%)	 2(8.7)	 0(0)	 0.523†	 0.470	
	
ANT	Overall	RT	
						Mild	
						Moderate	
									
	
	
3(13.0)	
1(4.3)	
	
	
	
2(8.7)	
1(4.3)	
	
	
1.000†	
0.470†	
	
	
0.000	
0.523	
Alerting		
						Mild		
						Moderate	
	
6(26.1)	
1	(4.3)	
	
4(17.4)	
0(0.0)	
	
0.475	
1.000†	
	
0.511	
0.000	
	
Orienting	
						Mild	
						Moderate	
	
	
3	(13.0)	
1(4.3)	
	
	
3(13.0)	
0(0.0)	
	
	
0.661†	
1.000†	
	
	
0.192	
0.000	
	
Conflict	
	 	 	 	
						Mild	
						Moderate	
5(21.7)	
2	(8.7)	
3(13.0)	
1(4.3)	
0.151†	
1.000†	
0.698	
0.000	
Note:	Values	are	n	(%	of	group)	classified	as	clinically	impaired.		
p-values	based	on	chi-square	and	yate’s	chi-square†.		
*statistically	significant	
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Correlational	analysis	
Table	 4	 provides	 a	 summary	 of	 exploratory	 correlational	 analyses	 examining	 relationships	
between	 participant	 characteristics	 and	 attention	 measure	 performance.	 Few	 significant	
correlations	 were	 observed.	 However,	 age	 (r	 =	 0.453,	 p	 =0.03)	 and	 self-reported	 levels	 of	
depression	 (r	 =	 0.415,	 p	 =	 0.049)	 were	 found	 to	 correlate	 with	 increasing	 RTs	 in	 control	
participants.		Similarly,	a	positive	correlation	was	identified	between	years	of	education	and	ANT	
accuracy	(r	=	0.419,	p	=	0.047),	while	increased	anxiety	correlated	with	better	SCWT	performance	
(r	=	0.449,	p	=	0.032).	These	relationships	were	not	observed	in	COPD	participants.	However,	a	
negative	relationship	was	identified	between	age	and	ANT	accuracy	(r	=	-0.503,							p	=	0.009)	in	
this	target	group.		The	orienting	effect	also	appeared	to	correlate	positively	with	length	of	time	
since	diagnosis	(r	=	0.479,	p=	0.021)	and	negatively	with	self-reported	anxiety					(r	=	-0.492,	p	=	
0.017).	 However,	 as	 these	 analyses	 were	 not	 corrected	 for	 multiple	 correlations,	 caution	 in	
interpretation	is	required.		
		
Table	4:	Correlations	between	measures	of	attention	and	participant	characteristics	
	
	 SCWT	 HSCT	
Errors		
HSCT	
Total	
ANT		
Grand	RT	
ANT	
Accuracy	
ANT	
Alerting	
ANT	
Orienting	
ANT	
Conflict	
AGE	
COPD		
																	p-value	
																	rho	
Controls		
																	p-value	
																	rho	
	
	
	
0.131	
-0.324	
	
0.067	
-0.388	
	
	
0.087	
-0.365	
	
0.381	
-0.192	
	
	
0.100	
-0.351	
	
0.639	
-0.103	
	
	
0.484	
0.154	
	
0.030*	
0.453	
	
	
0.009*	
-0.530	
	
0.295	
-0.228	
	
	
0.862	
0.038	
	
0.796	
0.057	
	
	
0.183	
0.288	
	
0.127	
0.328	
	
	
0.441	
0.169	
	
0.791	
-0.059	
EDUCATION	
COPD		
																	p-value	
																	rho	
Controls		
																	p-value	
																	rho	
	
	
	
0.937	
0.017	
	
0.219	
0.266	
	
	
0.570	
0.125	
	
0.375	
0.194	
	
	
0.554	
0.130	
	
0.531	
0.138	
	
	
0.250	
-0.250	
	
0.590	
0.119	
	
	
0.199	
0.278	
	
0.047*	
0.419	
	
	
0.823	
0.049	
	
0.741	
0.073	
	
	
0.347	
0.205	
	
0.512	
-0.144	
	
	
0.614	
0.111	
	
0.182	
0.288	
PACK	YEARS	
COPD		
																	p-value	
																	rho	
Controls		
																	p-value	
																	rho	
	
	
0.338	
-0.209	
	
0.231	
0.260	
	
	
0.790	
0.059	
	
0.220	
0.266	
	
	
0.895	
0.029	
	
0.206	
0.274	
	
	
0.614	
0.111	
	
0.641	
-0.103	
	
	
0.354	
-0.203	
	
0.911	
-0.025	
	
	
0.846	
0.043	
	
0.332	
-0.212	
	
	
0.889	
0.031	
	
0.149	
-0.311	
	
	
0.529	
-0.138	
	
0.105	
-0.347	
ANXIETY	
COPD		
																	p-value	
																	rho	
Controls		
																	p-value	
																	rho	
	
	
	
0.749	
-0.071	
	
0.032*	
0.449	
	
	
0.403	
-0.183	
	
0.714	
-0.081	
	
	
0.687	
-0.089	
	
0.365	
-0.198	
	
	
0.637	
0.104	
	
0.617	
0.110	
	
	
0.285	
0.233	
	
0.816	
-0.051	
	
	
0.295	
0.228	
	
0.398	
-0.185	
	
	
0.017*	
-0.492	
	
0.861	
-0.039	
	
	
0.698	
0.085	
	
0.200	
0.278	
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	 SCWT	 HSCT	
Errors		
HSCT	
Total	
ANT		
Grand	RT	
ANT	
Accuracy	
ANT	
Alerting	
ANT	
Orienting	
ANT	
Conflict	
DEPRESSION	
COPD		
																	p-value	
																	rho	
Controls		
																	p-value	
																	rho	
	
	
0.404	
0.183	
	
0.723	
0.078	
	
	
0.546	
-0.133	
	
0.637	
-0.104	
	
	
0.606	
-0.113	
	
0.177	
-0.291	
	
	
0.248	
0.251	
	
0.049*	
0.415	
	
	
0.138	
0.319	
	
0.259	
-0.246	
	
	
0.682	
-0.090	
	
0.583	
0.121	
	
	
0.626	
-0.107	
	
0.567	
-0.126	
	
	
0.479	
0.155	
	
0.777	
0.063	
COPD	ONLY		
DURATION		
					p-value	
																	rho	
	
	
0.310	
-0.221	
	
	
0.771	
0.064	
	
	
0.872	
-0.035	
	
	
0.725	
0.078	
	
	
0.919	
-0.022	
	
	
0.208	
-0.273	
	
	
0.021*	
0.479	
	
	
0.987	
0.003	
MRC	
																	p-value	
																	rho	
	
0.387	
0.189	
	
0.556	
-0.129	
	
0.457	
-0.163	
	
0.161	
0.302	
	
0.856	
-0.040	
	
0.203	
-0.276	
	
0.359	
-0.200	
	
0.555	
0.130	
FEV1(%pred.)	
																	p-value	
																	rho	
	
0.232	
-0.259	
	
0.570	
-0.125	
	
0.823	
-0.049	
	
0.573	
0.124	
	
0.316	
-0.219	
	
0.503	
-0.147	
	
0.717	
-0.080	
	
0.396	
-0.186	
Note:	values	are	spearman’s	rho.	
*statistically	significant	
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DISCUSSION	
	
The	current	study	investigated	differences	in	attention-based	performance	between	stable	
COPD	participants	and	healthy	age-matched	controls.	Direct	comparison	of	individual	subtest	
scores	found	no	significant	differences	between	the	two	groups.		
	
Examination	 of	 ANT	 reaction	 times	 highlighted	 prolonged	 RTs	 across	 both	 groups,	 in	
comparison	to	the	participants	in	Klein	et	al.	(2009).	This	difference	may	be	best	explained	by	
the	impact	of	aging	on	the	older	samples	included	in	the	present	study.	Nonetheless,	a	smaller	
between-group	effect	size	was	noted.	This	suggests	that,	although	COPD	may	generally	have	
a	slightly	negative	influence	on	response	speed,	the	extent	of	response	slowing	seems	more	
substantial	during	exacerbation.	These	patterns	are	consistent	with	a	recent	study	comparing	
healthy	controls	to	stable	and	exacerbating	groups	(Dodd	et	al.,	2013).	While	both	patient	
groups	performed	poorer	 than	controls,	processing	speed	 in	 the	exacerbating	participants	
was	significantly	slower	than	the	stable	group.	This	prospective	investigation	also	observed	
some	 improvement	 of	 these	 difficulties	 three	 months	 after	 exacerbation.	 Nevertheless,	
processing	speed	difficulties	in	stable	cohorts	have	been	reported	previously	(Liesker	et	al.,	
2004;	 Karakontaki	 et	 al.,	 2013).	 The	 SCWT	 has	 also	 been	 used	 to	 examine	 this	 function,	
evaluating	the	speed	at	which	participants	read	a	simple	word	list	aloud	(Liesker	et	al.,	2004;	
Cleutjens	et	al.,	2017).	However,	critical	interpretation	of	this	subtest	highlights	the	confound	
of	breathlessness	on	speaking	rate	in	a	COPD	population.	Therefore,	slower	reading	speeds	
observed	in	this	group	may	be	independent	of	processing	speed	issues	and,	for	this	reason,	
the	SCWT	was	not	used	for	this	purpose	in	the	current	study.		
	
	 71	
Compared	to	the	findings	of	Klein	et	al.	(2009),	the	small	effect	size	of	ANT	accuracy	suggests	
stable	 patients	 may	 make	 less	 errors	 than	 exacerbating	 counterparts	 on	 simple	 visual	
perception	 tasks.	 	However,	 further	examination	of	 individual	participant	scores	 identified	
two	patients	whose	accuracy	rates	were	particularly	 low	(<75%).	As	no	such	outliers	were	
observed	in	the	control	group,	these	difficulties	with	response	accuracy	in	a	small	sub-group	
of	this	stable	sample	may	be	noteworthy.	This	observation	also	gives	weight	to	a	previous	
study	which	demonstrated	“concentration	faults”	in	stable	COPD	participants	on	a	driving-
based	assessment	(Orth	et	al.,	2008).	
	
Between-group	effect	sizes	in	ANT	alerting	were	relatively	equivalent	to	those	identified	in	
Klein	et	al.	 (2009).	Such	similar	 findings	would	suggest	 that	COPD	patients,	 in	any	disease	
phase,	may	be	less	vigilant	than	their	peers	and	gain	less	benefit	from	alarm	cues.	In	contrast,	
the	current	study’s	selective	attention	(orienting)	results,	assessed	by	the	spatial	orienting	
effect,	 differ	 from	 those	 of	 Klein	 et	 al.	 (2009).	While	 this	 study	 of	 exacerbating	 patients	
demonstrated	a	 small	 to	medium	negative	effect	 size,	 the	 current	 investigation	 identified	
little	between-group	difference.	Equivalent	proportions	of	each	group	were	deemed	as	mildly	
impaired	on	this	subtask	and,	while	performance	of	one	COPD	participant	was	suggestive	of	
moderate	 impairment,	 it	 is	 unclear	 whether	 this	 result	 is	 clinically	meaningful.	 Relatively	
intact	 selective	 attention	 abilities	 in	 stable	 COPD	 have	 also	 been	 illustrated	 elsewhere	
(Karakontaki	et	al.,	2013).	These	findings	suggest	that	exacerbation	may	have	a	differential	
impact	on	spatial	selective	attention.		
	
The	current	study	utilised	two	additional	measures,	alongside	the	ANT	conflict	component,	
to	 examine	 response	 inhibition.	 Firstly,	 the	 substantial	 variability	 observed	 in	 individual	
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participant’s	conflict	effects	should	be	noted.	The	distribution	of	these	scores,	particularly	for	
the	COPD	group,	 necessitated	non-parametric	 analyses.	Nevertheless,	 consistent	with	 the	
findings	 of	 Klein	 et	 al.	 (2009),	 between-group	 negative	 effect	 sizes	 on	 this	 measure	 of	
executive	attention	were	small.	Interestingly,	condition-specific	accuracy	analysis	identified	
that	the	two	COPD	participants	marked	as	impaired	for	overall	accuracy,	demonstrated	very	
poor	accuracy	(<20%)	and	substantially	prolonged	RTs	in	the	incongruent	condition.	Similar	
patterns	 were	 also	 observed	 in	 the	 HSCT	 with	 response	 inhibition	 errors	 indicating	
impairment	 in	 several	 participants	 across	 both	 groups,	 although	 impairment	 was	 slightly	
more	common	in	the	COPD	group	(34.8%	vs	21.7%).	Given	the	demographic	characteristics	
of	 the	sample,	 such	high	 frequencies	of	 impairment	may	be	explained	by	 the	 influence	of	
higher	education	levels	in	the	original	HSCT	normative	sample.	Alternatively,	these	findings	
may	be	related	to	age,	which	is	not	addressed	in	the	scoring	procedures	of	this	test.	As	the	
between-group	differences	in	occurrence	of	impairment	are	relatively	small	across	both	these	
measures,	it	is	unclear	whether	these	findings	have	clinical	importance.		
	
In	examination	of	SCWT	performance,	a	small	to	medium	negative	effect	size	was	observed	
when	comparing	the	two	groups.	In	addition,	significantly	more	COPD	patients	than	controls	
were	marked	as	mildly	impaired	on	this	task.	Findings	of	other	studies	utilising	the	SCWT	in	
stable	COPD	groups	have	been	mixed.	While	 Cleutjens	et	 al.	 (2017)	 reported	 significantly	
reduced	performance	 in	COPD	patients,	 in	comparison	to	controls,	a	similar	 study	did	not	
support	these	findings	(Pereira	et	al.,	2011).	Notably,	both	Liesker	et	al.	(2004)	and	Ryu	et	al.	
(2013)	identified	significantly	diminished	performance	only	in	a	sub-group	of	participants	with	
severe	 COPD.	 No	 difficulties	 were	 reported	 in	 the	 moderate	 group.	 Executive	 attention	
dysfunction	 on	 the	 attentional	 switching	 sub-task	 of	 the	 Trail-making	 test	 has	 also	 been	
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indicated	 by	 several	 studies	 (Grant	 et	 al.,	 1982;	 Liesker	 et	 al.,	 2004;	 Dodd	 et	 al.,	 2013).	
However,	this	trend	did	not	appear	to	generalise	to	a	more	complex	task	examining	driving-
related	 executive	 abilities	 	 (Karakontaki	et	 al.,	 2013).	 These	 findings,	 taken	 together	with	
those	of	the	current	study,	seem	to	suggest	that	stable	COPD	participants	may	be	at	some	
increased	 risk	 of	 experiencing	 executive	 attention	 difficulties	 and,	 in	 particular,	 a	 small	
proportion	may	experience	impairment	sufficient	to	impact	on	day-to-day	functioning.			
	
However,	 as	 previously	 mentioned,	 care	 is	 required	 when	 interpreting	 SCWT	 results	 in	
respiratory	groups.		Most	studies	utilising	this	measure	examined	response	inhibition	as	the	
number	of	 correct	 responses	 in	a	given	 time,	 compared	 to	age	normed	data.	 	Due	 to	 the	
impact	 of	 breathlessness	 on	 speaking	 rate,	 this	 method	 does	 not	 adequately	 examine	
response	inhibition	in	COPD	patients.		This	issue	was	given	some	consideration	by	Cleutjens	
et	al.,	(2017)	through	calculation	of	an	interference	score,	subtracting	the	mean	score	of	the	
Colour-Word	trial	from	the	Colour	and	Word	subtest	scores.	However,	only	the	current	study	
utilised	the	interference	calculation	recommended	by	Golden	and	Freshwater,	(2002).	This	
method	accounts	for	individual	variability	in	reading	speed	through	the	discrepancy	between	
a	predicted	colour-word	score,	calculated	using	the	previous	subtest	scores,	and	observed	
performance.		
	
The	 main	 findings	 of	 the	 current	 study	 are	 insufficient	 to	 support	 hypothesis	 one.	 No	
statistically	significant	differences	were	identified	in	between-group	comparisons	of	attention	
task	 performance.	 However,	 examination	 of	 effect	 sizes	 suggested	 reduced	 alerting	 and	
response	inhibition	in	the	COPD	group.	Furthermore,	for	a	small	subgroup,	these	difficulties	
met	criteria	for	clinical	impairment.	The	attention	performance	observed	in	this	stable	COPD	
cohort	 is	 somewhat	discordant	with	patterns	detected	on	similar	 tasks	 in	an	exacerbating	
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group	(Klein	et	al.,	2009).	However,	consistent	with	this	previous	investigation,	all	effect	sizes	
observed	 in	 the	 present	 study	 indicated	 some	 detrimental	 influence	 of	 COPD	 across	 all	
attention	 components	 investigated.	 This	 may	 suggest	 a	 graded	 detrimental	 impact	 of	
worsening	health	status,	which	differentially	 influences	subcomponents	of	attention.	Such	
patterns	 are	 supported	 by	 the	 findings	 of	 a	 prospective	 study	 (Dodd	 et	 al.,	 2013).		
Interestingly,	in	comparison	to	Klein	et	al.	(2009),	larger	negative	effect	sizes	were	observed	
across	 all	 measures	 of	 response	 inhibition.	 This	 pattern	 would	 suggest	 that	 stable	 COPD	
participants	may	experience	greater	difficulties	with	executive	attention	than	exacerbating	
counterparts.	 However,	 the	 observed	 effect	 sizes	 on	 ANT	 conflict	 relatively	 small	 in	 both	
studies.	 Therefore,	 it	 seems	 likely	 that	 other	measures,	 particularly	 the	 SCWT,	may	 have	
increased	sensitivity	for	executive	attention	abilities	when	appropriately	applied	in	this	health	
group.		
	
	
The	results	of	this	study	do	little	to	support	hypothesis	two.	Few	correlations	were	identified	
between	participant	characteristics	and	attention	scores.	Despite	the	observation	of	some	
significant	correlations	in	demographics	and	performance	of	the	control	group,	these	were	
not	noted	in	the	COPD	group.	This	may	suggest	that	the	factors	influencing	attention	abilities	
in	this	group	may	be	more	complex.	However,	few	significant	relationships	were	observed	
between	attention	task	performance	and	disease-related	variables.	Therefore,	based	on	the	
findings	 of	 the	 current	 study,	 the	 pathology	 underlying	 any	 attention-based	 difficulties	 in	
stable	COPD	patients	remains	unclear.		
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	Clinical	Implications		
The	 findings	 of	 this	 study	 suggest	 that,	 for	 most	 stable	 COPD	 patients,	 any	 attention	
difficulties	experienced	are	unlikely	to	have	a	meaningful	impact	upon	everyday	functioning.	
Therefore,	routine	screening	of	attention	abilities	may	not	be	warranted	in	this	population.		
However,	 respiratory	 clinicians	 should	 be	 aware	 that	 a	 small	 sub-group	 are	 at	 risk	 of	
experiencing	 attentional	 impairment.	 For	 these	 individuals,	 additional	 support	 and	
adaptations	to	routine	care	may	aid	self-management	abilities	and	improve	clinical	outcomes.		
Allowing	additional	processing	time	and	providing	repetition	of	small	chunks	of	information	
may	support	treatment	compliance	and	patient’s	awareness	of	their	condition.	Confirmation	
of	 understanding	during	 clinical	 conversations	may	highlight	 any	 information	 lost	 through	
concentration	 lapses.	 Difficulties	 with	 response	 inhibition	 may	 imply	 impaired	 impulse	
control.	Clinicians	should	be	mindful	of	 the	 influence	of	 this	problem	on	health	behaviour	
change.	Targeted	support	and	encouragement	for	lifestyle	changes	may	prove	beneficial	for	
these	individuals.		
	
Limitations		
Given	the	observed	effect	sizes,	the	sample	size	of	the	present	study	was	not	large	enough	to	
identify	 significant	 differences	 between	 groups.	 Recruitment	 of	 additional	 participants,	 as	
initially	planned,	may	have	led	to	stronger	conclusions.	However,	examination	of	the	largest	
effect	size	on	the	ANT	(d	=	0.52),	would	suggest	the	initial	target	would	still	be	insufficient	and	
a	sample	of	60	participants	per	group	would	be	required.	The	ANT	itself	has	some	limitations,	
with	 indications	 that	 split-half	 reliabilities	 may	 be	 low	 for	 alerting	 and	 orienting	 effects,	
though	moderately	high	for	executive	control	(MacLeod	et	al.	2010).	Participants	in	this	study	
also	 reported	 mental	 fatigue	 due	 to	 the	 repetitive	 nature	 of	 this	 measure,	 this	 was	 not	
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addressed	in	experimental	design.	A	shortened	version	of	this	test	is	available	but	has	not	yet	
been	fully	validated.	Therefore,	to	allow	useful	comparison	with	the	findings	of	Klein	et	al.	
(2009),	the	original	ANT	was	deemed	most	suitable	for	the	current	investigation.		The	use	of	
the	HSCT	may	also	be	criticised	as	it	has	not	been	validated	for	use	in	a	respiratory	population.	
However,	it	is	routinely	used	in	neuropsychological	assessments	of	older	adults.		
	
Limitations	of	the	impairment	analyses	should	also	be	noted.	Firstly,	no	published	norms	are	
available	for	the	ANT.	Classification	of	impairment	on	this	task	was	limited	to	deviations	from	
control	groups	means.	 It	 is	not	possible	to	determine	how	closely	these	scores	 fit	a	 larger	
sample	 of	 the	 general	 population.	 Furthermore,	 classification	 of	 impairment	 varied	
somewhat	between	attention	measures	and	HSCT	sten	scores	provide	a	crude	classification	
system.	A	relatively	low	Z-score	cut	off	(>1SD	below	mean)	for	mild	impairment	classification	
may	explain	why	clinical	levels	of	difficulties	were	identified	in	some	controls.	For	this	reason,	
Z-scores	of	>2SD	below	means	were	also	employed	to	explore	differences	in	magnitude	of	
impairment	between	groups.		
	
It	should	be	noted	that	this	study	did	not	account	for	the	influence	of	circulating	blood	gases	
or	history	of	exacerbations	which,	as	previously	documented,	may	have	a	role	in	mediating	
cognitive	 dysfunction.	 However,	 methodological	 and	 resource	 constraints,	 in	 addition	 to	
problems	with	patient	self-report,	prevented	the	collection	of	this	data.	Lastly,	recruitment	
for	this	study	took	place	at	a	secondary	care	level	despite	most	interventions	for	stable	COPD	
being	provided	within	primary	care	settings.	Due	to	the	presumed	reduction	in	health	status	
of	the	patients	in	this	study,	cognitive	difficulties	in	primary	care	patients	may	be	less	likely.				
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Future	Research	
	
Although	this	investigation	has	taken	some	steps	to	explore	the	correspondence	in	attention	
functions	between	exacerbating	and	stable	phases	of	COPD,	it	is	not	possible	to	effectively	
establish	whether	these	findings	were	influenced	by	individual	premorbid	abilities.	 	Future	
research	 should	 aim	 to	 address	 this	 issue	 by	 conducting	 prospective	 studies	 examining	
cognitive	 abilities	 prior	 to,	 during	 and	 post-exacerbation.	 	 Given	 the	 executive	 problems	
suggested	by	this	study,	further	examination	of	other	higher-order	abilities,	such	as	planning	
and	self-monitoring,	may	highlight	clinically	useful	implications	for	COPD	care.		
	
	
CONCLUSIONS	
	
The	 current	 study	 was	 the	 first	 investigation	 to	 take	 a	 theoretically	 driven	 approach	 to	
examine	attention	functions	in	stable	COPD.		Direct	comparison	of	individual	subtest	scores	
identified	no	significant	between-group	differences.	Trends	in	effect	sizes	and	frequency	of	
impairment	indicated	that	stable	COPD	patients	may	have	some	mild	difficulties	in	attention	
tasks.	 However,	 a	 small	 subgroup	may	 experience	 substantial	 impairment	 that	 negatively	
influences	functional	abilities	and	clinical	outcomes.		
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Appendix	1.2		
QUALITY	RATING	PROTOCOL	
	
Author	and	year:		
	
SECTION	1:	INTERNAL	VALIDITY	
	
Study	question	
	 	 	 	 	 	 	 	 	 Circle	response		
1.1	 The	study	addresses	an	appropriate	and	clearly	
focussed	question	
Yes																								No		
Can’t	say	
	
Selection	of	subjects		
	
1.2	 The	cases	and	controls	are	taken	from	
comparable	populations	
Yes																								No		
Can’t	say	
1.3	 The	same	exclusion	criteria	are	used	for	both	
cases	and	controls	
	
Controls	will	differ	in	one	exclusion	criteria	with	
regards	to	disease	status	e.g.	will	not	have	
diagnosis	of	Chronic	Obstructive	Pulmonary	
Disease	or	any	other	respiratory	disease.	
	
	
Yes																								No	
Can’t	say	
1.4	 Comparison	is	made	between	participants	(cases	
and	controls)	and	non-participants	(eligible	to	
participate	but	did	not	take	part)	to	establish	
their	similarities	or	differences.	
 
 
	
	
Yes																								No	
Can’t	say	
1.5	 Cases	are	clearly	defined	and	differentiated	from	
controls		
Yes																								No	
Can’t	say	
1.6	 It	is	clearly	established	that	controls	are	non-
cases		
Yes																								No	
Can’t	say	
	
Assessment		
	
1.7	 Evidence	from	other	sources	is	used	to	
demonstrate	that	the	method	of	outcome	
assessment	is	valid	and	reliable.	
	
Yes																								No	
Can’t	say	
	
Confounding		
	
1.8	 The	main	potential	confounders	are	identified	
and	taken	into	account	in	the	design	and	analysis.	
Yes																								No	
Can’t	say	
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Statistical	Analysis	
	
1.9	 Confidence	intervals	are	provided.	 Yes																								No	
	
	
SECTION	2:	OVERALL	STUDY	
	
2.1	 How	well	was	the	study	done	to	reduce	the	risk	
of	confounding	or	bias?		
	
High	quality	(++)	=	Majority	of	criteria	met	(6	or	
more	yes	responses).	Little	or	no	risk	of	bias.	
Results	unlikely	to	be	changed	by	further	
research.	
	
Acceptable	(+)	=	Most	of	criteria	met	(4	or	more	
yes	responses).	Some	flaws	in	the	study	with	an	
associated	risk	of	bias.	Conclusions	may	change	
in	the	light	of	other	studies.	
	
Unacceptable	(0)	=	Either	most	criteria	not	met	
or	significant	flaws	relating	to	key	aspects	of	
study	design.	Conclusions	likely	to	change	in	the	
light	of	further	studies.	
	
	
	
	
	
	
	
High	quality			(++)	
Acceptable						(+)	
Unacceptable	(0)	
	
2.2	 Taking	into	account	clinical	considerations,	
your	evaluation	of	the	methodology	used	and	
the	statistical	power	of	the	study,	do	you	think	
there	is	clear	evidence	of	an	association	
between	exposure	and	outcome?	
	
	
	
Yes																								No	
Can’t	say	
2.3	 Are	the	results	of	this	study	directly	applicable	to	
the	patient	group	targeted	by	this	review?	
	
	
Yes																								No	
	
	
NOTES	
Add	any	comments	on	your	own	assessment	of	the	study	and	the	extent	to	which	it	
answers	your	question.	Mention	any	areas	of	uncertainty	raised	above.	
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Appendix	1.3	
Data	Extraction	Proforma	
	
AUTHOR:		 YEAR:			
TITLE:		
STUDY	CHARACERISTICS	
Purpose/aims	of	study:		
	
PARTICIPANT	CHARACTERISTICS	
Type	of	COPD	and	Disease	Stage:		
Age	Range	for	COPD	group:		 	
Age	Range	for	Control	Group:		 	
Gender	COPD	Group:		 	 	
Gender	Control	Group	 	 	
Matching:	
		
RECRUITMENT	
Number	of	COPD	participants:	 	
Number	of	control	participants:	 	
Recruitment	method	of	COPD	participants:	
	
Recruitment	method	of	control	participants:	
	
INCLUSION/EXCLUSION	
Inclusion	criteria:	
	
Exclusion	criteria:		
		
MEASURES	
What	were	the	measures	of	cognitive	function?	
	
RESULTS	
What	type	of	analysis	was	used?	
	
What	were	the	results?		
		
CONCLUSIONS	
	What	were	the	main	findings/conclusions	of	the	study?	
	
Limitations:	
	
QUALITY	RATING	
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Appendix	1.4	
	
	
GOLD	Severity	Assessment	Guidelines	
	
Prior	to	2011:	Assessment	solely	based	on	degree	of	airflow	limitation	(FEV1%pred)	
	
Classification	 Severity	of	airflow	limitation	 FEV1	(%	predicted)	
GOLD	1	 Mild	 ≥ 80 
GOLD	2	 Moderate	 50	-79	
GOLD	3	 Severe	 30	-	49	
GOLD	4	 Very	severe	 <30	
	
	
2011	onwards:		Combined	assessment	of	severity.	Degree	of	airflow	limitation	above,	in	
addition	to	number	of	exacerbations	per	year	and	self-report	of	symptoms	(Medical	
Research	Council	Breathlessness	Scale	score)	
	
	 Characteristic	 Spirometric	
classification	
Exacerbations	
per	year	
	
MRC	
A	 Low	risk	
Less	symptoms	
GOLD	1-2	 ≤ 1 
	
0	–	1	
B	 Low	risk	
More	symptoms	
GOLD	1-2	 ≤ 1 ≥	2	
C	 High	risk	
Less	symptoms	
GOLD	3-4	 ≥	2	 0	-1	
D	 High	risk	
More	symptoms	
GOLD	3-4	 ≥	2	 ≥	2	
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Appendix	1.5	
	
Quality	Rating	Scores	
	
	
	 1.1	 1.2	 1.3	 1.4	 1.5	 1.6	 1.7	 1.8	 1.9	 2.1	 2.2	 2.3	 Yin1	
Borson	 Y	 CS	 Y	 N	 Y	 CS	 Y	 N	 N	 +	 Y	 Y	 4	
Cleutjens	 Y	 Y	 Y	 N	 Y	 Y	 Y	 Y	 N	 ++	 Y	 Y	 7	
Dodd	 Y	 Y	 CS	 Y	 Y	 Y	 Y	 N	 N	 ++	 Y	 Y	 6	
Grant	 Y	 Y	 CS	 CS	 Y	 Y	 CS	 N	 N	 +	 CS	 Y	 4	
Incalzi	 Y	 Y	 Y	 N	 Y	 N	 Y	 N	 N	 +	 Y	 Y	 5	
Karakontaki	 Y	 CS	 Y	 N	 Y	 CS	 Y	 N	 N	 +	 Y	 Y	 4	
Liesker	 Y	 Y	 Y	 CS	 Y	 CS	 CS	 N	 N	 +	 Y	 Y	 4	
Ortapamuk	 Y	 CS	 CS	 CS	 Y	 Y	 Y	 N	 N	 +	 CS	 Y	 4	
Ryu	 Y	 CS	 Y	 N	 Y	 Y	 CS	 N	 N	 +	 CS	 Y	 4	
Spilling		 Y	 CS	 Y	 N	 Y	 Y	 CS	 N	 N	 +	 Y	 Y	 4	
Zhang	 Y	 CS	 Y	 N	 Y	 N	 Y	 N	 N	 +	 Y	 Y	 4	
Y	=	yes,	N	=	No,	CS	=	Can’t	say
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Appendix	1.6	
Cognitive	domain	 Test	names		
Processing	speed		 Digit	symbol/coding	
Symbol	search	
Letter-digit	substitution	
Reaction	Time	to	Single	Visual	and	Acoustic	Stimuli		
Attention/working	memory	 Digit	span	
Spatial	span	
Visual	memory	
Letter-number	sequencing	
Mental	control	
Selective	attention	test		
Perception	 Rhythm	test	
Speech-sound	perception	test	
Sensory	examination	
Tachistoscopic	Traffic	Test	
Language	 Boston	naming	test	
Aphasia	screen	
Construction	 Rey	Complex	Figure	Test	(Copy)	
Coping	drawings	with	and	without	landmarks	
Tactual	performance	test	(spatial	relations)	
Motor	 Tapping	test	
Groove	peg	board		
Memory	
Verbal	
	
	
	
Non-verbal	
	
Word	lists		
Story	recall/logical	memory	
Verbal	paired	associated	
Verbal	visual	learning	task	
Rey	Complex	Figure	Test		
Visual	paired	associated	
Visual	reproduction	
Figural	memory		
Tactual	performance	test	
Concept	formation	and	abstract	reasoning		 Raven’s	progressive	matrices	
Temporal	rule	induction	
Category	test		
Arithmetic	
Executive	functions		 Verbal	fluency		
Trail	making	test	
Stroop	task		
Concept	shifting	test		
Zoo	Map	
Key	Search		
Permanent	Attention	Test		
NB:	A	number	of	different	versions/variations	of	many	of	these	measures	are	available	and	were	
utilised	across	different	studies.	This	table	provides	a	simplified	summary.		
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Appendix	2.7	
        
Centre Number:
Study Number:
Patient Identification Number for this trial:  
 
CONSENT FORM 
(For those with a diagnosis of Chronic Obstructive Pulmonary Disease)
Title of Project: “An Investigation of Attentional Functions in Stable COPD” 
Name of Researcher: Claire Alexander      Please initial box 
1. I confirm that I have read and understand the information sheet 
dated ...................... (version ............) for the above study. I have had the  
opportunity to consider the information, ask questions and have had these  
answered satisfactorily.  
 
2. I understand that my participation is voluntary and that I am free to withdraw  
at any time, without giving any reason, without my medical care or legal  
rights being affected.  
 
3. I understand that relevant sections of my medical notes and data collected  
during the study, may be looked at by individuals from regulatory authorities  
or from the NHS Health Board, where it is relevant to my taking part in this 
research. I give permission for these individuals to have access to my records.  
 
4. I consent to the researchers obtaining my most recent spirometry (lung  
function) results from my clinical care team 
 
 
5. I agree to take part in the above study.  
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Name of Patient   Date     Signature  
 
 
 
  
Name of person taking consent Date    Signature 
(if different from researcher) 
 
 
 
Researcher    Date    Signature 
 
 
 
 
If you would like your GP to be informed of your participation in the study please provide their 
contact details below.  
 
Name of GP Practice:  
 
Address:  
	
	
	
 
 
 
 
If you would like to receive a written summary report of the study findings, please provide details 
for where this should be mailed to below.  
 
 
Name:  
 
 
Address:  
 
 
 
 
Postcode:  
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Appendix	2.8	
        
Centre Number:
Study Number:
Patient Identification Number for this trial:  
 
CONSENT FORM 
(For Healthy Volunteers)
Title of Project: “An Investigation of Attentional Functions in Stable COPD” 
Name of Researcher: Claire Alexander      Please initial box 
6. I confirm that I have read and understand the information sheet 
dated ...................... (version ............) for the above study. I have had the  
opportunity to consider the information, ask questions and have had these  
answered satisfactorily.  
 
7. I understand that my participation is voluntary and that I am free to withdraw  
at any time, without giving any reason, without my medical care or legal  
rights being affected.  
 
8. I agree to take part in the above study.  
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Name of Patient   Date      Signature    
 
 
 
  
Name of person taking consent Date     Signature 
(if different from researcher) 
 
 
 
 
Researcher    Date     Signature 
 
 
 
 
If you would like to receive a written summary report of the study findings, please provide details 
for where this should be mailed to below.  
 
 
Name:  
 
 
Address:  
 
 
 
 
Postcode: 
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Appendix	2.9	
	
        
“An Investigation of Attentional Functions in Stable COPD” 
 
Participant Information Sheet 
(For those with a diagnosis of Chronic Obstructive Pulmonary Disease) 
 
Invitation to take part in the research  
You are invited to take part in a research project. We are looking for adults aged 18 and 
over who have a diagnosis of Chronic Obstructive Pulmonary Disease (COPD) which is 
currently stable, have had no previous neurological conditions (e.g. Traumatic Brain 
Injury; Stroke), do not have severe sensory deficits (e.g. partial or complete blindness), 
and do not have other health conditions which significantly impact on their ability to 
engage with the tasks.  
 
Before deciding whether you want to participate or not it is important to understand why 
this research is being carried out and what taking part will involve. This information is 
outlined below. Please take the time to read this carefully and, if you wish, discuss it 
with others. If there is anything that is unclear or you would like more information on, 
please do not hesitate to ask. Take time to decide whether you would like to take part. 
Thank you for taking the time to read this information sheet.  
	
Who is conducting the research?  
The research project is being conducted by Claire Alexander (Trainee Clinical 
Psychologist), Dr Jim Law (Clinical Psychologist, NHS Highland), Dr Sue Turnbull and 
Professor Jonathan Evans from the Institute of Health and Well-being at the University 
of Glasgow. The study is being carried out to fulfil academic requirements for the 
University of Glasgow’s Doctorate in Clinical Psychology degree course.  
	
What is the purpose of the study?  
(i)Background 
Chronic Obstructive Pulmonary Disease (COPD) is predominantly a respiratory 
condition. However, many people with COPD also experience several other difficulties 
including high blood pressure, reduced mobility and anxiety. Difficulties vary a lot 
between people with COPD, and not everyone has difficulties in all these areas. In this 
project, we are particularly interested in how COPD might impact on brain functioning 
(cognition). There is emerging evidence that COPD may have some impact on the brain 
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structure and function and this could affect how information is processed. Specifically, 
we are interested in a kind of brain function, attention. Attention is the brain’s way of 
processing information which we take in from the environment through our senses (for 
example, through seeing or hearing things). There are different types of attention, the 
most well-known types are: how we select information from the environment to attend 
to; and how long we can concentrate on something.  Previous work by other 
researchers has suggested that some people with COPD may have difficulties with 
some types of attention.  However, as this research is still in its infancy it is difficult to 
draw helpful conclusions from these studies. Several studies have also focussed on 
examining cognitive functioning while COPD patients are acutely unwell and staying in 
hospital. For this project, we wanted to examine COPD patients whose condition is 
currently stable as this represents most COPD patients. Problems with cognition during 
a stable phase of COPD may have important implications on patient’s quality of life.  If 
we find that attention is affected in stable COPD, this may therefore help us identify 
strategies that help people with COPD manage their treatment and daily activities. 
 
In this project we will measure different types of attention using a few different tasks. 
These will involve looking at a computer screen and responding to some visual stimuli, 
reading some words on a card and completing some sentences. Each of these tasks 
focus on particular components of attention based on established neuropsychological 
models of attention. In addition, we will investigate whether attention varies with disease 
severity and other important factors such as age or anxiety.  
(ii) Aims  
To investigate: (1) Whether individuals with stable COPD perform differently on 
attention tasks compared to people who do not have COPD; and (2) If there is a 
relationship between attention performance and other relevant factors such as disease 
severity. 
 
What does taking part involve?  
If you would like to take part, we will arrange a time convenient to you to come along 
and meet our researcher. Typically, the appointments would take place in an NHS 
building however if necessary it may be possible for the researcher to visit you at home.  
 
Participation involves completing some assessment measures which, in total, will take 
approximately 30-60 minutes. First, we will collect some demographic information such 
as age and any medication you might be taking. With your permission, we would also 
like to access information about your most recent lung function tests. We will use this 
information, to see if whether your lung functioning has any relationship with your 
performance on the tasks. We will also ask you to complete a short questionnaire about 
your mood.  
 
You will then be asked to complete three different tasks. One task will involve looking at 
a computer screen and responding to visual stimuli which is presented. A second task 
will involve reading information from a sheet of paper.  The last task will involve 
completing several sentences which will be read out to you.	With your permission, we 
will also inform your GP that you are participating in this study. 	
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What are the possible benefits of taking part?  
Research gives us the opportunity to improve our knowledge about various difficulties 
people with COPD may experience. Your participation in this study will help us increase 
our knowledge about cognition and attention in individuals with COPD and help us 
make improvements to treatment in the future.  
 
What are the possible risks or disadvantages of taking part?  
There are no significant risks or disadvantages of taking part in this study.  Although we 
do not predict that participating in this study will cause you any distress, if this were to 
happen we would help you access appropriate support.  
 
Do I have to take part?  
It is up to you whether you decide to take part in this study. If you decide you want to 
take part, you will be given a copy of this information sheet to keep and be asked to sign 
a consent form. Although you will be signing the consent form, please be aware that you 
are free to withdraw from the study at any time. A decision to withdraw from the study or 
not take part at all will have absolutely no impact on the standard of care you receive.  
 
Will my information be confidential?  
All information collected about you during the study will be kept strictly confidential. If 
any information about you was required to leave the hospital, your name and address 
will be removed so that you cannot be recognised from it.  
 
What happens to the information?  
Your personal information and identity will be kept strictly confidential and known only 
by the researchers. Information will be stored within a locked filing cabinet in the locked 
Psychology Department. All information will be held in accordance to the Data 
Protection Act (1998), meaning that it be stored securely and not shared with other 
people without your permission. If any findings from this study are published, your 
identity will be anonymised so you are not identifiable.  
 
What will happen to the results of the study?  
At the end of the study, the finished report will be submitted to the University of 
Glasgow. We hope that the findings will be published in a medical journal and through 
other sources to make sure the general public know what the study found. If you wish, 
you will be sent a written summary report of the findings. Your identity and personal 
information will not be reported or published following this study.  
 
Who is funding the research?  
The research is funded by the Doctorate in Clinical Psychology course at the University 
of Glasgow.  
 
Who has reviewed the study?  
The study has been reviewed by Glasgow University to make sure that it meets 
standards outlined regarding scientific conduct. The Proportionate Review Sub-
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Committee of the NRES Committee West-Midlands South Birmingham has also 
reviewed this study to make sure that it meets standards outlined regarding ethical 
conduct.  
 
Who can I contact for further information?  
If you would like any additional information or have any questions, please do not 
hesitate to contact a member of the research team on the below contact details.  
Alternatively, if you would like to speak to someone independent to the study please use 
the below contact details. Please also use the independent contact information if you 
wish to raise a complaint. 
 
RESEARCH TEAM: 
Name Role Contact 
Claire Alexander Trainee Clinical 
Psychologist,  
NHS Highland 
Drumossie Unit,  
New Craigs Hospital, 
 Inverness,  
IV3 8NP 
Tel: 01463 704683 
Dr Sue Turnbull and 
Professor Jon Evans 
Academic 
Supervisors, 
University of Glasgow 
University of Glasgow  
1st Floor, Administration Building,  
Gartnavel Royal Hospital,  
1055 Great Western Road, Glasgow,  
G12 0XH  
Tel: 0141 211 0607 
Dr Jim Law Field Supervisor, 
NHS Highland 
Drumossie Unit,  
New Craigs Hospital, 
Inverness,  
IV3 8NP 
Tel: 01463 704683 
 
INDEPENDENT CONTACT:  
Name  Role  Contact  
Professor Thomas 
McMillan  
Independent 
Contact, 
University of 
Glasgow  
University of Glasgow  
1st Floor, Administration Building,  
Gartnavel Royal Hospital,  
1055 Great Western Road, Glasgow,  
G12 0XH  
Tel: 0141 211 0607 
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Appendix	2.10	
        
“An Investigation of Attentional Functions in Stable COPD” 
 
Participant Information Sheet 
(For Healthy Volunteers) 
Invitation to take part in the research  
You are invited to take part in a research project. This project is investigating 
attention in people with Chronic Obstructive Pulmonary Disease (COPD), but in 
addition, we need a group of healthy people with whom to compare the participants 
with COPD. We are looking for adults aged 18 and over who do not have a diagnosis 
of Chronic Obstructive Pulmonary Disease (COPD) have had no previous 
neurological conditions (e.g. Traumatic Brain Injury; Stroke), do not have severe 
sensory deficits (e.g. partial or complete blindness), and do not have other health 
conditions which significantly impact on their ability to engage with the tasks.  
 
Before deciding whether you want to participate or not it is important to understand 
why this research is being carried out and what taking part will involve. This 
information is outlined below. Please take the time to read this carefully and, if you 
wish, discuss it with others. If there is anything that is unclear or you would like more 
information, please do not hesitate to ask. Take time to decide whether you would 
like to take part. Thank you for taking the time to read this information sheet.  
 
Who is conducting the research?  
The research project is being conducted by Claire Alexander (Trainee Clinical 
Psychologist), Dr Jim Law (Clinical Psychologist; NHS Highland), Dr Sue Turnbull 
and Professor Jonathan Evans from the Institute of Health and Well-being at the 
University of Glasgow. The study is being carried out to fulfil academic requirements 
for the University of Glasgow’s Doctorate in Clinical Psychology degree course.  
 
What is the purpose of the study?  
(i)Background 
Chronic Obstructive Pulmonary Disease (COPD) is predominantly a respiratory 
condition. However, many people with COPD also experience several other 
difficulties including high blood pressure, reduced mobility and anxiety. Difficulties 
vary a lot between people with COPD, and not everyone has difficulties in all these 
areas. In this project, we are particularly interested in how COPD might impact on 
brain functioning (cognition). There is emerging evidence that COPD may have 
some impact on the brain structure and function and this could affect how 
information is processed. Specifically, we are interested in a kind of brain function, 
attention. Attention is the brain’s way of processing information which we take in 
from the environment through our senses (for example, through seeing or hearing 
things). There are different types of attention, the most well-known types are: how 
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we select information from the environment to attend to; and how long we can 
concentrate on something.  Previous work by other researchers has suggested that 
some people with COPD may have difficulties with some types of attention.  
However, as this research is still in its infancy it is difficult to draw helpful conclusions 
from these studies. Several studies have also focussed on examining cognitive 
functioning while COPD patients are acutely unwell and staying in hospital. For this 
project, we wanted to examine COPD patients whose condition is currently stable as 
this represents most COPD patients. Problems with cognition during a stable phase 
of COPD may have important implications on patient’s quality of life.  If we find that 
attention is affected in stable COPD, this may therefore help us identify strategies 
that help people with COPD manage their treatment and daily activities.  
 
In this project, we will measure different types of attention using a few different tasks. 
These will involve looking at a computer screen and responding to some visual 
stimuli, reading some words on a card and completing some sentences. Each of 
these tasks focus on particular components of attention based on established 
neuropsychological models of attention. In addition, we will investigate whether 
attention varies with disease severity and other important factors such as age or 
anxiety.  
	
(ii) Aims  
To investigate: (1) Whether individuals with stable COPD perform differently on 
attention tasks compared to people who do not have COPD; and (2) If there is a 
relationship between attention performance and other relevant factors such as 
disease severity. 
 
What does taking part involve?  
If you would like to take part, we will arrange a time convenient to you to come along 
and meet our researcher. Typically, the appointments would take place in an NHS 
building however if necessary it may be possible for the researcher to visit you at 
home.  
 
Participation involves completing some assessment measures which, in total, will 
take approximately 30-60 minutes. First, we will collect some demographic 
information such as age and any medication you might be taking. We will also ask 
you to complete a short questionnaire about your mood.  
 
You will then be asked to complete three different tasks. One task will involve looking 
at a computer screen and responding to visual stimuli which is presented. A second 
task will involve reading information from a sheet of paper.  The last task will involve 
completing several sentences which will be read out to you.		
 
What are the possible benefits of taking part? 
Research gives us the opportunity to improve our knowledge about various 
difficulties people with COPD may experience. Your participation in this study will 
help us increase our knowledge about cognition and attention in individuals with 
COPD and help us make improvements to treatment in the future.  
 
What are the possible risks or disadvantages of taking part?  
There are no significant risks or disadvantages of taking part in this study.  Although 
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we do not predict that participating in this study will cause you any distress, if this 
were to happen we would help you access appropriate support.  
 
Do I have to take part?  
It is up to you whether you decide to take part in this study. If you decide you want to 
take part, you will be given a copy of this information sheet to keep and be asked to 
sign a consent form. Although you will be signing the consent form, please be aware 
that you are free to withdraw from the study at any time. A decision to withdraw from 
the study or not take part at all will have absolutely no impact on the standard of care 
you receive.  
 
Will my information be confidential?  
All information collected about you during the study will be kept strictly confidential. If 
any information about you was required to leave the hospital, your name and 
address will be removed so that you cannot be recognised from it.  
 
What happens to the information?  
Your personal information and identity will be kept strictly confidential and known 
only by the researchers. Information will be stored within a locked filing cabinet in the 
locked Psychology Department. All information will be held in accordance to the Data 
Protection Act (1998), meaning that it be stored securely and not shared with other 
people without your permission. If any findings from this study are published, your 
identity will be anonymised so you are not identifiable.  
 
What will happen to the results of the study?  
At the end of the study, the finished report will be submitted to the University of 
Glasgow. We hope that the findings will be published in a medical journal and 
through other sources to make sure the general public know what the study found. If 
you wish, you will be sent a written summary report of the findings. Your identity and 
personal information will not be reported or published following this study.  
	
Who is funding the research?  
The research is funded by the Doctorate in Clinical Psychology course at the 
University of Glasgow.  
 
Who has reviewed the study?  
The study has been reviewed by Glasgow University to make sure that it meets 
standards outlined regarding scientific conduct. The Proportionate Review Sub-
Committee of the NRES Committee West-Midlands South Birmingham has also 
reviewed this study to make sure that it meets standards outlined regarding ethical 
conduct.  
 
Who can I contact for further information?  
If you would like any additional information or have any questions, please do not 
hesitate to contact a member of the research team on the below contact details. 
Alternatively, if you would like to speak to someone independent to the study please 
use the below contact details. Please also use the independent contact information if 
you wish to raise a complaint.  
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RESEARCH TEAM: 
Name	 Role	 Contact	
Claire Alexander Trainee Clinical 
Psychologist,  
NHS Highland 
Drumossie Unit,  
New Craigs Hospital, 
Inverness,  
IV3 8NP 
Tel: 01463 704683 
Dr Sue Turnbull and 
Professor Jon Evans 
Academic Supervisors, 
University of Glasgow 
University of Glasgow  
1st Floor, Administration Building,  
Gartnavel Royal Hospital,  
1055 Great Western Road, 
Glasgow,  
G12 0XH  
Tel: 0141 211 0607 
Dr Jim Law Field Supervisor, 
NHS Highland 
Drumossie Unit,  
New Craigs Hospital, 
Inverness,  
IV3 8NP 
Tel: 01463 704683 
 
INDEPENDENT CONTACT:  
Name  Role  Contact  
Professor Thomas 
McMillan  
Independent Contact,  
University of Glasgow  
University of Glasgow  
1st Floor, Administration Building,  
Gartnavel Royal Hospital,  
1055 Great Western Road, 
Glasgow,  
G12 0XH  
Tel: 0141 211 0607 
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An	Investigation	of	Attentional	Functions	in	Stable	COPD		
	
Abstract		
Background:	There	is	growing	evidence	to	suggest	that	patients	with	Chronic	Obstructive	
Pulmonary	Disease	(COPD)	may	experience	some	cognitive	difficulties	across	several	
different	domains.	Due	to	the	complex	nature	of	the	condition	and	co-morbidities,	the	
underlying	pathological	mechanisms	influencing	cognition	remains	unclear.	In	addition,	
variation	in	experimental	design	has	led	to	inconsistent	findings.	A	previous	study	found	
significant	differences	between	COPD	patients	and	controls	in	attentional	functions.	
However,	the	study	recruited	an	inpatient	population	of	medically	unwell	COPD	patients.		
Aims:	This	study	aims	to	take	a	theoretically	driven	approach	to	examine	of	attentional	and	
executive	functions	in	stable	COPD	patients.		
Methods:	A	between-subjects	design	will	be	used	to	compare	cognitive	performance	
between	COPD	patients	and	controls	on	the	Attentional	Network	Task,	Colour-Word	Stroop	
Task	and	Hayling	Sentence	Completion	task.		
Practical	applications:	Clinical	management	of	COPD	may	be	better	informed	by	greater	
awareness	of	cognitive	abilities	of	COPD	patients.	Exploring	strategies	to	compensate	for	
difficulties	in	attention	may	help	with	treatment	compliance,	symptom	management	and	
quality	of	life.		
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Introduction	
Chronic	obstructive	pulmonary	disease	(COPD)	is	an	umbrella	term	for	several	conditions	
causing	progressive	and	irreversible	damage	to	the	airways.	These	conditions	predominantly	
include	chronic	bronchitis	and	emphysema,	typically	associated	with	inflammatory	
responses	to	noxious	particles	through	cigarette	smoking	or	occupational	exposure	(GOLD,	
2016).	There	is	growing	evidence	to	suggest	that	cognitive	impairments	may	be	noted	in	
COPD	patients.	Such	difficulties	may	impair	activities	of	daily	living	(Antonelli-Incalzi	&	
Corsonello,	2008)	and	coexist	with	problems	in	treatment	compliance	(Allen	et	al,		2003).		
	
Reports	on	the	occurrence	of	cognitive	impairment	in	COPD	range	between	3.9%	(Chang	et	
al,	2012)	to	77%	(Grant	et	al,	1982).	Deficits	have	been	suggested	across	multiple	cognitive	
domains	(Cleutjens	et	al.,	2017;	Dodd	et	al.,	2010;	Lahousse	et	al,	2015;	Torres-sánchez	et	
al.,	2015).		However,	the	research	appears	to	have	taken	an	exploratory	approach,	
examining	cognition	as	one	of	many	disease	related	variables	and	its	influence	on	outcomes	
such	as	admissions,	rehabilitation	and	morbidity.	While	these	studies	have	led	to	interesting	
conclusions,	findings	seem	inconsistent	and	variation	in	experimental	design	has	led	to	
difficulties	in	interpretation.		
	
The	complexity	of	assessing	cognitive	impairment	in	COPD	arises	in	the	interaction	of	
disease	related	variables	and	co-morbidities.	Several	studies	have	aimed	to	explore	the	
underlying	pathology	of	deficits	noted	with	multifactorial	models	of	cognitive	impairment	
proposed	(Andreou	et	al,	2014;	Dodd	et	al,	2010).	Primary	disease	presentation	is	reduced	
lung	function,	often	leading	to	imbalance	of	circulating	blood	gases.	Evidence	suggests	that	
hypercapnia,	abnormally	elevated	blood	carbon-dioxide	level,	and	hypoxemia,	abnormally	
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low	blood	oxygen	concentration,	may	have	a	role	in	mediating	cognitive	impairment	in	the	
disease	(Borson	et	al.,	2008;	Grant	et	al.,	1987;	Klein	et	al,	2009;	Ortapamuk	&	Naldoken,	
2006;	Stuss	et	al,	1997).	Studies	have	also	found	reduced	cerebral	perfusion	and	metabolic	
activity	within	frontal,	subcortical	and	parietal	areas	during	hypoxemia	(Incalzi	et	al.,	2003;	
Ortapamuk	&	Naldoken,	2006).	MRI	studies	revealed	atrophy	in	several	brain	regions	
including	cortex,	hippocampus,	and	striatum,	suggesting	that	chronic	hypoxemia	may	
influence	cognition	through	hypoxic	neuronal	damage	(Maiti	et	al,	2008).	In	addition,	
hypoxemia	may	affect	neural	signalling,	impacting	oxygen	dependent	enzymes	required	for	
neurotransmitter	synthesis	(Grant	et	al,	1987).		
	
Suggestions	have	been	made	that	the	physiological	circumstances	of	COPD	may	induce	
systemic	cerebral	changes	through	oxidative	stress,	inflammatory	cytokines	and	increased	
thrombotic	factors	(Borson	et	al.,	2008)	and	exacerbate	co-existing	risk	of	cerebral	
atherosclerosis,	commonly	related	to	smoking	history.	Co-morbid	cardiovascular	disease	is	
common	in	COPD,	occurring	in	more	than	half	of	hospital	admissions	(Fioravanti,	1995).	
Therefore,	primary	disease	presentation	may	influence	cerebrovascular	risk	factors,	a	notion	
supported	by	evidence	on	the	influence	of	COPD	in	small	vessel	disease	(Lahousse	et	al.,	
2015).	Lastly,	several	cognitive	deficits	have	been	noted	in	Obstructive	Sleep	Apnoea	(Incalzi	
et	al.,	2003;	Grant	et	al.,	1987)	frequently	co-existing	with	COPD.	It	has	been	suggested	that	
nocturnal	hypoxemia	and	sleep	disruption	may	explain	shared	cognitive	impairment.	
Therefore,	COPD	may	facilitate	chronic	haemodynamic	imbalance.		
	
Given	such	a	presentation,	cognitive	impairment	in	COPD	may	be	expected	in	relation	to	
oxygen	sensitive	neuroanatomical	regions,	namely	the	hippocampus,	basal	ganglia	and	
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cerebral	cortex	(Paola	et	al.,	2008).	To	date,	the	literature	suggests	cognitive	impairments	in	
the	domains	of	perception	(Anontelli-Incalzi	et	al.,	2006),	attention	(Orth	et	al.,	2006),	
memory	(Antonelli-Incalzi	&	Corsonello,	2008;	Fioravanti	et	al.,	1995)	and	executive	function	
(Incalzi	et	al,	2003;	Grant	et	al,	1982)	.	Yet	many	of	these	studies	have	lacked	a	theoretically	
driven	approach	to	neuropsychological	investigation	and	findings	have	been	inappropriately	
generalised.		
	
Klein	et	al	(2009)	utilised	the	Attentional	Network	Test	(Fan	et	al,	2002)	to	explore	
attentional	networks	of	alerting,	orienting	and	executive	control	proposed	by	Posner	and	
Petersen	(2012).	The	paper	defined	alerting	as	achieving	and	maintaining	an	alert	state;	
orienting	is	the	selection	of	information	from	sensory	input.	Executive	control	is	defined	as	
resolving	conflict	among	responses,	overcoming	a	strong	habitual,	pre-potent	response.	
Klein	(2009)	found	prolonged	reaction	times	and	significant	impairment	in	alerting	and	
orienting	in	COPD	patients	compared	to	controls.	No	significant	differences	were	found	
between	groups	for	executive	control.	Similarly,	a	study	by	Liesker	et	al	(2004)	found	no	
significant	differences	between	controls	and	COPD	patients	on	the	Colour-Word	Stroop	
Task.		However,	the	validity	of	these	results	is	unclear	as	the	findings	were	adjusted	based	
on	normative	data	which	is	not	identified.	In	contrast,	a	recent	study,	utilising	a	simpler	
scoring	system	found	strong	effect	sizes	of	COPD	on	Stroop	task	performance	(Cleutjens	et	
al.,	2017).		
	
Therefore,	there	is	emerging	but	inconsistent	evidence	suggesting	attentional	deficits	may	
arise	in	COPD.	However,	a	key	criticism	of	Klein	et	al’s	(2009)	study	is	its	limitation	of	
inpatient	participant	recruitment.	There	are	several	physiological	factors	which	may	
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influenced	cognitive	performance	in	such	a	medically	unstable	sample	and	may	confound	
the	results.	Such	a	sampling	method	limits	the	generalisability	of	findings	and	neglects	the	
most	common,	stable	and	community	dwelling	COPD	population.	Due	to	its	increased	
influence	on	community	outcomes,	it	is	important	that	cognition	in	COPD	is	examined	
during	stable	disease	stage.	Therefore,	the	current	study	aims	to	build	on	the	existing	
neuropsychological	literature	in	COPD	by	examining	attentional	functions	in	community	
dwelling	stable	COPD	patients.		
	
Hypotheses	
3. Performance	on	attentional	tasks	will	be	significantly	poorer	in	COPD	patients	than	
controls		
a. COPD	patients	will	show	significant	impairment	in	alerting,	orienting	and	
executive	components	of	the	attention	network	test	in	comparison	to	
controls		
b. COPD	patients	will	perform	poorer	than	controls	on	other	measures	of	
response	inhibition	(Hayling	and	Stroop)	
c. Cognitive	performance	will	negatively	correlate	with	increasing	age,	disease	
severity	and	levels	of	anxiety	and	depression	
Plan	of	Investigation	
Participants	
Participants	will	be	persons	with	a	diagnosis	of	COPD	and	control	subjects	matched	for	age	
and	gender.	The	study	aims	to	recruit	30	participants	in	each	group.	COPD	patients	will	be	
recruited	via	community	respiratory	nurses.	Control	participants	will	include	a	convenience	
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sample	of	friends/family	of	COPD	participants	and	others	may	be	recruited	through	NHS	
emails,	hospital/community	noticeboards.	
Inclusion	and	Exclusion	Criteria	
• Inclusion	criteria	for	COPD	participants:		
o Diagnosis	of	COPD	-	diagnosed	prior	to	participation,	according	to	GOLD	
(2016)	guidelines		
o Have	attended	annual	COPD	review	and	completed	lung	function	tests		
o COPD	is	considered	clinically	stable,	classified	in	line	with	the	GOLD	(2016)	
strategic	document	
• Exclusion	criteria	for	COPD	and	controls:	
o Presence	of	major	psychiatric	disorders		
o History	of	neurodegenerative	disease	or	neurological	disorder	or	event	e.g.	
stroke		
o Significant	sensory	impairment	or	co-morbid	health	conditions	which	may	
affect	participation		
o Non-native	English	speaker	
Recruitment		
Individuals	who	have	a	diagnosis	of	COPD,	and	are	under	the	care	of	community	respiratory	
nurses,	will	be	invited	to	participate	in	the	study.	Participants	who	meet	participation	
criteria	will	be	informed	of	the	study	by	a	respiratory	nurse	during	routine	appointments.	If	
the	individual	consents,	the	researcher	will	contact	potential	participants	to	provide	them	
with	more	information.	Arrangements	will	then	be	made	for	task	administration.	
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All	participants	will	be	given	an	information	sheet	outlining	the	project	procedures.	
Participants	will	be	informed	that	they	can	withdraw	from	the	study	at	any	time.	If	they	
choose	to	take	part,	participants	will	complete	written	consent	forms.		
	
Measures		
Administered	at	appointment:		
• Demographic	information	collection:		
o Age,	gender,	education,	occupation,	medical	history,	current	medication,	
smoking	history		
o Current	treatment,	onset	and	years	of	illness	-	COPD	patients	only	
• Medical	Research	Council	Breathlessness	Scale	-	COPD	patients	only	
• Hospital	Anxiety	and	Depression	Scale	(Zigmond	and	Snaith,	1983)	
• Attention	Network	Test	(Fan	et	al.,	2002)	
• Hayling	Sentence	Completion	Test		(Burgess	and	Shallice,	1996)	
• Stroop	Colour-Word	Test	(Golden,	1978;	2002)	
Collected	via	respiratory	care	team:	
NHS	Highland	complies	with	GOLD	(2016)	COPD	management	guidelines,	ensuring	annual	
respiratory	review	via	primary	care.	Utilising	this	care	pathway,	this	study	will	collect	up	to	
date	spirometry	(lung	function)	data.	As	the	participants	will	be	under	the	care	of	
respiratory	nurses,	it	is	expected	that	the	spirometry	data	will	be	accessed	via	these	
clinicians.	However,	there	may	be	a	small	number	of	cases	where	that	data	must	be	sought	
from	primary	care	clinicians.	
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Design		
A	between-subjects	design	will	be	used	to	examine	differences	in	attentional	and	executive	
functions	between	COPD	and	control	participants.	A	within-subjects	design	will	be	used	to	
examine	the	association	between:	lung-function;	MRC	score;	smoking	pack	years;	age;	
depression;	anxiety	and	attention	performance.		
	
Test	procedures		
Informed	consent	will	be	obtained	from	each	participant,	including	consent	to	access	
respiratory	data.	
The	researcher	will	ensure	that	COPD	participants	have	taken	their	respiratory	treatment	
(e.g.	bronchodilator	inhaler)	as	prescribed,	ensuring	optimum	respiratory	functioning	during	
testing	procedures.		
	
Demographic	Information	
At	the	task	administration	appointment,	demographic	information	will	be	collected	first.	In	
addition,	the	Hospital	Anxiety	and	Depression	Scale	will	be	completed.	COPD	patients	will	
also	be	asked	to	complete	the	MRC	breathlessness	scale	questionnaire.		
	
Attention	Network	Test	(ANT)	
All	participants	will	then	be	asked	to	complete	the	Attention	Network	Test.	The	ANT	is	a	
computer	based	reaction	time	task	for	assessing	alerting,	orienting	and	executive	
components	of	attention.		Through	pressing	arrows	on	a	computer	keyboard,	participants	
will	be	required	to	indicate	whether	an	arrow	presented	on	a	screen	points	left	or	right.	This	
arrow	will	be	presented	under	several	different	conditions	to	manipulate	alerting,	orienting	
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and	executive	factors.	To	examine	alerting	the	arrow	will	be	presented	at	varying	delays	
from	cue	presentation.	To	influence	orienting	the	arrow	will	be	presented	following	varying	
spatial	cues.	To	influence	conflict	(executive	component)	the	arrow	will	be	presented	with	
flankers	which	are	congruent	or	incongruent	with	the	target	arrow	direction.	The	ANT	
includes	a	practice	block	then	three	assessment	blocks.	A	critical	appraisal	of	the	
psychometric	properties	of	the	test	has	been	conducted	by	(Macleod	et	al.,	2010).	Split	half	
reliabilities	of	reaction	times	were	found	to	be	low	for	alerting	and	orienting	and	moderate	
high	for	executive	control.	There	is	also	some	evidence	to	suggest	that	the	networks	
examined	may	interact.	Therefore,	the	ANT	may	be	somewhat	limited	in	examining	the	
attentional	networks	proposed	by	Posner	and	Petersen.	However,	we	would	argue	the	ANT	
is	useful	to	make	comparisons	with	Klein	(2009).		
	
Colour-Word	Stroop	Task		
All	participants	will	then	be	asked	to	complete	the	Stroop	Colour-Word	Test,	another	
measure	of	response	inhibition.		There	are	several	variations	available	of	the	Stroop	task.	
The	version	administered	by		Cleutjens	et	al	(2017)	is	not	available	in	English.	Therefore,	it	is	
proposed	that	this	study	utilise	(Golden,	1978;	2002),	the	most	commonly	used	format	in	
English,	which	has	three	parts.		In	the	first	trial	participants	are	asked	to	read	aloud	names	
of	colours	which	are	printed	in	black	ink.	In	the	second	the	participants	are	asked	to	name	
patches	of	colours.	Lastly,	participants	are	asked	to	state	the	colour	which	the	word	is	
printed	in	which	is	different	from	the	word	itself.	e.g.	the	correct	response	to	the	word	
“red”	printed	in	blue	ink	would	be	“blue”.	Scoring	will	correspond	with	the	method	used	in	
Cleutjen’s	(2017)	Errors	and	completion	time	for	trials	are	measured.	The	time	needed	for	
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the	last	card	will	be	subtracted	from	the	mean	score	for	the	first	and	second	cards	to	obtain	an	
interference	score.		
	
Hayling	Test		
All	participants	will	then	be	asked	to	complete	the	Hayling	test.	This	test	is	made	up	of	two	
parts	and	aims	to	detect	difficulties	with	response	inhibition.	The	first	part	requires	the	
participant	to	complete	a	series	of	sentences	with	a	meaningful	word.	Next,	the	participant	
is	asked	to	complete	the	sentence	with	an	irrelevant	word	that	does	not	“fit”	sensibly	in	the	
sentence.		
The	Hayling	test	has	been	found	to	have	good	test-retest	reliability	(r=0.72–0.93)	and	
internal	consistency	(α=0.62–0.76)	in	a	range	of	patients	with	neurological	disorders	
(Burgess	&	Shallice,	1997).	
	
It	is	estimated	that	testing	will	take	approximately	30	to	60	minutes.		
	
Data	Analysis	
• Descriptive	statistics	will	be	produced	to	describe	the	data.		
• Independent	Samples	T	tests,	Mann-Whitney	U	and	Chi-Square	tests	will	be	used	as	
appropriate	to	compare	COPD	and	control	groups	on	demographic	information,	and	
to	compare	groups	on	attentional	task	performance.		
• Pearson	Correlation	coefficients	(r)	or	non-parametric	equivalents	will	be	used	to	
explore	relationships	between	lung	function,	MRC	scale,	HADs,	age,	pack	years,	and	
attention	scores.		
Justification	of	sample	size		
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In	their	examination	of	attentional	function	in	an	inpatient	COPD	population,	Klein	et	al	
(2009)	found	medium	effect	sizes	in	examining	alerting	and	orienting	(d	=	0.48-0.61).	Using	
G	Power,	with	power	set	at	0.8,	alpha	at	0.05	(two-tailed),	d=0.61,	sample	size	estimations	
suggest	that	44	participants	per	group	are	required.	However,	examining	a	stable	outpatient	
COPD	patients,	Cleutjens	et	al	(2017)	a	found	an	effect	size	of	d=0.85	on	Stroop	Task	
performance.	Using	G	power	under	these	conditions	generates	a	sample	size	requirement	of	
23	participants	per	group.	We	would	note	that	the	Cleutjen’s(2017)	sample	fits	more	closely	
with	the	population	of	interest	in	this	study.	Therefore,	considering	recruitment	feasibility	
and	methodological	variations	within	these	previous	investigations,	we	would	
conservatively	propose	aiming	to	recruit	30	participants	for	this	study.		
	
Settings	and	Equipment	
Efforts	will	be	made	to	ensure	task	administration	will	occur	within	a	clinic	room	within	NHS	
Highland.	However,	if	participants	are	unable	to	travel,	home	visits	may	be	necessary.		
The	Attention	Network	Test	is	presented	electronically	through	E-prime	on	a	computer,	it	
will	be	necessary	to	borrow	a	University	laptop	for	this	purpose.		
	
Health	and	Safety		
Researcher	safety		
Home	visits	will	be	avoided	if	possible.	If	necessary,	NHS	Highlands	procedures	and	the	
University	of	Glasgow	guidance	on	lone	working	procedures	will	be	followed.		
Please	see	appendix	1	for	more	details.	
	
Participant	safety	
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The	task	does	not	involve	physical	exertion.	However,	should	the	participant	become	
distressed	or	breathless	the	task	will	be	stopped.	Permission	will	be	sought	for	the	
researcher	to	contact	an	appropriate	clinician	should	the	participant	present	with	significant	
exacerbation	of	COPD	symptoms	and	participation	would	be	terminated.	If	the	participant	
presents	with	symptoms	of	anxiety	or	other	mental	health	concerns	the	researcher	will	
signpost	them	to	local	support.		
For	full	details	of	Health	and	Safety	Issues	see	appendix	1.	
	
Ethics	
Ethical	approval	will	also	be	sought	through	the	NHS	Integrated	Research	Approval	System.	
Data	collection,	storage	and	analysis	will	occur	while	following	the	principles	of	the	Data	
Protection	Act	(1998),	NHS	Highland	and	the	University	of	Glasgow	guidelines.		
	
Financial	Issues		
For	full	details	of	expenses	see	appendix	2.	
Timetable	
	For	full	timetable	please	see	appendix	4.	
Practical	Applications		
If	cognitive	impairment	affecting	attention	difficulties	is	noted	for	individuals	with	COPD,	it	
will	be	necessary	to	take	this	into	consideration	in	clinical	practice.	Exploring	strategies	to	
compensate	for	this	difficulty	may	help	with	treatment	compliance,	symptom	management	
and	quality	of	life.		
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Appendix	2.12	
	
	
	
	 	
MRC Dyspnoea Scale  
1  Breathless only with strenuous exercise  
2  Short of breath when hurrying on the level or up a slight hill.  
3  Slower than most people of the same age on a level surface or Have to stop when walking at my own pace on the level.  
4  Stop for breath walking 100 meters orAfter a walking few minutes at my 
own pace on the level  
5  Too breathless to leave the house.  
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Appendix	2.13	
	
ATTENTION	NETWORK	TASK	INSTRUCTIONS:		
This	is	an	experiment	investigating	attention.		
You	will	be	shown	an	arrow	on	the	screen	pointing	either	to	the	left	or	right.		
	
	
	
	
Your	task	is	to	press	the	left	arrow	key	on	your	keyboard	when	the	central	arrow	points	left	
and	the	right	arrow	key	when	it	points	right.		
	
On	some	trials	the	central	arrow	will	be	flanked	by	two	arrows	to	the	left	and	two	arrows	to	
the	right.		
Your	task	is	to	respond	to	the	direction	of	only	the	CENTRAL	arrow.	
	
	
	
	
	
Please	make	sure	you	respond	as	quickly	and	accurately	as	possible.		
	
Use	your	left	index	finger	for	the	left	arrow	key	and	your	right	index	finger	for	the	right	
arrow	key.		
	
There	will	be	a	cross	(“+”)	in	the	centre	of	the	screen	and	the	arrows	will	appear	either	
above	or	below	the	cross.	You	should	try	to	fixate	on	the	cross	throughout	the	experiment.	
Please	do	not	move	your	eyes	to	the	target.		
	
On	some	trials	there	will	be	asterisk	(*)	cues	indicating	when	or	where	the	arrow	will	occur.	
Try	to	maintain	fixation	on	the	cross	(“+”)	at	all	times.		
	
The	experiment	contains	4	blocks		
The	first	block	is	for	practice	and	takes	about	2	minutes		
The	other	three	blocks	are	experimental	blocks	and	each	takes	about	5	minutes.		
	
After	each	block	there	will	be	a	message	“take	a	break”	and	you	may	take	a	rest.		
	
Press	the	space	bar	to	begin	the	next	block.		
The	whole	experiment	takes	about	20	minutes.		
Any	questions?		
	
If	you	understand	the	instructions,	you	may	start	the	practice	session	
The	practice	trial	will	tell	you	whether	your	response	is	correct	or	incorrect.	
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Appendix	2.14	
	
	
ANT	STIMULI	
	
	
	
	
	
	
	
Cue	conditions	
No	cue	
	
	
	
	
Central	cue	
	
	
	
	
Double	cue	
	
	
	
	
	
Spatial	cue	
	
	
	
	
	
Flanker	conditions		
Congruent	
	
	
	
	
	
Incongruent	
	
	
	
	
	
Target	
*	
*	 *	
*	
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Appendix	2.15	
	
ANT	data	pre-processing	procedures	
Only	trial	data	from	the	experimental	assessment	blocks	were	included	in	the	analysis.	
Overall	accuracy	and	condition	accuracy	were	calculated.	Subsequently	incorrect	trials	and	
trials	with	a	reaction	time	<200ms	or	>2000ms	were	removed.	Outlier	analysis	was	also	
conducted	with	trials	above	or	below	2SDs	of	the	participant	specific	condition	mean	
removed.		Then	mean,	median	and	SD	were	calculated	for	each	individual	and	condition.		
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Appendix	2.17	
	
GOLD	Severity	Assessment	Guidelines	
	
Prior	to	2011:	Assessment	solely	based	on	degree	of	airflow	limitation	(FEV1%pred)	
	
Classification	 Severity	of	airflow	limitation	 FEV1	(%	predicted)	
GOLD	1	 Mild	 ≥ 80 
GOLD	2	 Moderate	 50	-79	
GOLD	3	 Severe	 30	-	49	
GOLD	4	 Very	severe	 <30	
	
	
2011	onwards:		Combined	assessment	of	severity.	Degree	of	airflow	limitation	above,	in	
addition	to	number	of	exacerbations	per	year	and	self-report	of	symptoms	(Medical	
Research	Council	Breathlessness	Scale	score)	
	
	 Characteristic	 Spirometric	
classification	
Exacerbations	
per	year	
	
MRC	
A	 Low	risk	
Less	symptoms	
GOLD	1-2	 ≤ 1 
	
0	–	1	
B	 Low	risk	
More	symptoms	
GOLD	1-2	 ≤ 1 ≥	2	
C	 High	risk	
Less	symptoms	
GOLD	3-4	 ≥	2	 0	-1	
D	 High	risk	
More	symptoms	
GOLD	3-4	 ≥	2	 ≥	2	
	
